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ABSTRACT 
Lung cancer is the leading cause of cancer-related death in both men and women, nationally 
and internationally and kills more people each year than breast, prostate, and colon cancers 
combined.  Non-small cell lung carcinoma (NSCLC) is the most common histological subtype of 
lung cancer, and accounts for 85% of all cases.  Cigarette smoking is the single greatest risk 
factor for lung cancer, and is correlated with 80-90% of all lung cancer deaths.  Nicotine, the 
addictive component of tobacco smoke, is not a carcinogen and cannot initiate tumors itself; 
however, it is known to act as a tumor promoter, by enhancing the proliferation, migration, and 
invasion of cells in vitro, thus accelerating tumor growth and metastasis in vivo.   Nicotine exerts 
is tumor promoting effects primarily by binding to, and activation of, nicotinic acetylcholine 
receptors (nAChRs), specifically the α7 subunit of nAChRs.  While α7 nAChR is expressed in a 
wide array of cells, how its expression is regulated is not fully understood.  Here we sought to 
elucidate the transcriptional regulation of α7 nAChR in NSCLC cells.  We report that α7 nAChR 
expression is induced by nicotine in an autoregulatory feedforward loop, and that the α7 gene 
promoter is differentially regulated by E2F1 and STAT1 transcription factors at an overlapping 
binding site suggesting a competitive interplay.  Depletion of E2F1 resulted in a reduced ability 
of nicotine to induce α7 nAChR, while depletion of STAT1 resulted in enhanced induction, 
suggesting that nicotine might use these two transcription factors to modulate the expression of 
α7 nAChR in a very precise fashion.  More recently, nicotine has been implicated in promoting 
self-renewal of stem-like side-population cells from lung cancers. Cancer stem-like cells have 
been implicated in tumor initiation as well as the maintenance, drug resistance, dormancy, 
recurrence, and metastasis of various tumor types.  We had previously shown that the 
embryonic stem cell transcription factor, Sox2, is indispensable for self-renewal of stem-like 
vii 
 
cells from lung adenocarcinoma cell lines; hence we sought to determine whether nicotine 
enhances stemness of lung cancer stem-like cells through Sox2.  We find that nicotine can 
induce the expression of Sox2 at the transcriptional level and this occurs through a nAChR-Src-
Yap1-E2F1 signaling axis.  Over recent years, electronic cigarettes (e-cigarettes) have emerged 
as healthy alternatives to traditional cigarette smoking as they do not contain tobacco; however, 
they do still contain nicotine. Our studies show that e-cigarette components can enhance tumor 
promoting properties of NSCLC cells similar to that observed with nicotine alone, and find that 
they can induce expression of Sox2 and mesenchymal markers as well as enhance migration 
and stemness of NSCLC cells.  Taken together, these studies reveal novel molecular 
mechanisms by which exposure to nicotine, via cigarette smoke or e-cigarettes, could alter the 
oncogenic potential of NSCLC cells. 
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CHAPTER ONE: 
INTRODUCTION 
Note to Reader 
Portions of this chapter have been previously published in Mol. Cancer Res.; 12(1); 4-23. And 
have been reproduced with permission from AACR Journals.  Author contributions: Schaal, C 
(writing, design, and figures), Chellappan, S., (writing, concept, and design).     
Lung Cancer and Smoking 
Despite growing knowledge of the disease and advanced treatment options, lung cancer 
remains the leading cause of cancer-related deaths in the United States and globally, in both 
genders, accounting for more deaths than breast, prostate, and colon cancers combined (1).  
There will be an estimated 224,390 new cases and 158,080 deaths due to lung cancer in 2016, 
and the 5-year survival rate is a bleak 15%.  There are two primary histological subtypes of lung 
cancer: small cell lung carcinoma (SCLC) comprising 15% of all lung cancers, and non-small 
cell lung carcinoma (NSCLC) which is the most common form, comprising 85% of all lung 
cancers (2).  NSCLC can be further characterized into squamous cell carcinoma (SCC) 
comprising 25-30%, adenocarcinoma compromising 40%, and large-cell carcinoma of the lung 
comprising 10-15% of cases (2, 3).  The standard of care for lung cancer patients is surgical 
resection for early stage disease (3, 4) (5); however, typically by the time a patient becomes 
symptomatic it is too advanced for surgery alone and has often metastasized, requiring adjuvant 
chemo or radiation therapies (6, 7).  With the advances in understanding the molecular 
mechanisms underlying this disease, treatment decisions are now based not only on stage and 
histological subtype of disease, but also on the genetic alterations present (6).  Common 
genetic alterations identified as drivers in lung cancer include mutations in EGFR, KRAS, 
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LKB1/STK11 genes, translocation of EML4-ALK, and loss of the tumor suppressors TP53 and 
RB (8).  Cancers harboring some of these alterations can be effectively targeted with agents 
including gefitinib and erlotinib for EGFR mutations, and crizotinib for EML4-ALK.  More 
recently, immunotherapies have emerged that target immune checkpoint molecules such as 
PD-1 and CTLA4 with agents like the anti-PD-1 antibody Nivolumab (Opdivo), which has shown 
clinical efficacy in some cohorts of lung cancer patients (9).  Albeit these recent advances in 
therapeutic modalities, even if the patient responds to either targeted or traditional lines of 
therapy, they tend to relapse with the appearance of metastatic disease, resulting in  mortality.  
All of this indicates a need to further study lung cancer and develop more efficacious, long 
lasting therapeutic modalities. 
Smoking is the single largest and most preventable risk factor for lung cancer, and is 
responsible for 70% of all NSCLC cases and 90% of SCLC cases; although there is a subset of 
lung cancer patients who develop the disease without a history of ever smoking (8, 10).  
Tobacco smoke contains 6,000 known carcinogens of various classes such as polycyclic 
aromatic hydrocarbons, tobacco specific nitrosamines, and aldehydes which are capable of 
initiating tumorigenesis (8, 11). Tobacco specific carcinogens like NNK (4-methylnitrosamino)-1-
(3-pyridyl)-1-butanone and NNN (N-nitrosonornicotine), which are nicotine derivatives,  act as 
mutagens primarily through the formation of DNA adducts resulting in mutation of vital genes 
like KRAS, p53, and RB (12).  While there are multiple nitrosamines present in tobacco, NNK 
and NNN have proven to be the most prevalent and potent, and are classified as Group 1 
carcinogens in humans (13).  They are present in tobacco as pro-carcinogens which require 
metabolic activation to exert their functions, and are unique in that they not only cause deletion 
mutations through DNA adducts, but can also bind to receptors to promoter pro-tumorigenic 
effects (13, 14).  NNN is produced by the nitrosation of nornicotine during the curing and 
processing of tobacco, as well as during the burning or smoking of tobacco (15).  NNK is 
naturally synthesized in tobacco leaves when they are exposed to light; upon exposure, the 
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purrolidine ring in nicotine opens up converting nicotine into NNK (16).  Most of the NNK and 
about half of the NNN found in tobacco smoke originates from burning (15, 16).   
Cancers such as melanoma are known to have high mutational burden, and not surprisingly, 
smoking-related lung cancer is reported be one of them, with a mean somatic mutation rate of 
8-10 mutations per 1 million base pairs compared to 0.8-1 mutations per million base pairs in 
never smokers (8, 17).  Tobacco exposure is additionally correlated with frequent cytosine-
adenine (C A) nucleotide transversions, substituting a purine for a pyrimidine or a pyrimidine 
with a purine, seen primarily in lung adenocarcinoma patients with a history of smoking as 
opposed to their non-smoking counterparts (17).  Overall this represents a complex disease and 
confounding clinical challenge, and a deeper understanding of the underlying mechanisms of 
smoking-related lung cancers is warranted. 
Nicotine, which is the addictive component of tobacco smoke, is generally thought to be non-
carcinogenic, though a recent study has suggested that chronic exposure at high concentrations 
could initiate muscle sarcoma in A/J mice (18, 19).  At the same time, nicotine has widely been 
shown to promote tumor growth and metastasis by inducing a number of tumor promoting 
properties including cell cycle progression, epithelial-to-mesenchymal transition (EMT), 
angiogenesis, migration, invasion, survival, and drug resistance in multiple tumor types (20-24).  
Additionally, nicotine has been shown to disrupt metabolic processes and induce the secretion 
of growth factors and cytokines altering the physiology of multiple organ systems (23, 25, 26).  
These observations suggest that nicotine contributes to the progression and metastasis of 
tumors in patients who continue to smoke. 
Nicotine Mediated Tumor Promotion 
The first set of  large-scale epidemiological studies causatively linked smoking to lung cancer in 
1950, which was then confirmed by the U.S. Surgeon General, the World Health Organization, 
and the Royal College of Physicians in London (26).  By 1988, tobacco smoke had already been 
well established as causative agent for multiple cancer types including those of the respiratory 
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tract, upper digestive system, bladder, renal, liver, and pancreas with suspicion for those of the 
cervix, head and neck which has since been confirmed (13).  The basis for this was linked to the 
nitrosamines NNN and NNK which were reported as being the strongest carcinogens present in 
tobacco and which had the ability to initiate tumors in rats, Syrian golden hamsters, and A/J 
mice; it is worth noting that NNK had strong propensity for inducing  lung cancers (27).  Initial 
reports investigating these nicotine derivatives found that while NNN and NNK could initiate 
tumors and promote proliferation, nicotine could not initiate tumors but had strong proliferative 
effects in neuroendocrine cells and lung tumors with neuroendocrine differentiation (28).  Since 
then, numerous studies have reported the proliferative effects of nicotine on both normal cells 
as well as tumor cells in vitro and in vivo, primarily through driving cell cycle progression (21, 22, 
29, 30).  Nicotine has been shown to promote proliferation in various cell types of the lung 
including neonatal rat lung tissue, normal human lung and airway cells, NSCLC, and SCLC; in 
addition to other organ specific cell types such as smooth muscle and endothelial cells, gingival 
fibroblasts, normal murine splenocytes, normal breast epithelium and breast cancers, head and 
neck cancers, cervical cancers, pancreatic cancers, colon cancers, cells in the immune 
compartment including promyelocytic leukemia cells (22, 31-40).  Conversely, nicotine has been 
shown to have a growth inhibitory effect on osteoblast and osteoblast-like cells which 
demonstrates a different role for nicotine in the bone compartment; the growth suppressive 
effect in the bone compartment is thought to have significant implications for the development of 
osteoporosis and bone loss associated with tobacco use (41, 42). 
Shortly after the reports of nicotine’s effects on proliferation, numerous studies found that 
nicotine could additionally enhance multiple aspects of tumor progression, which are 
summarized in Figure 1.1.  Nicotine is a potent angiogenic agent in endothelial cells involved in 
both the physiological and pathological process of angiogenesis, a phenomenon important for 
the growth and progression of cancer (43).  Studies found that nicotine could enhance 
angiogenesis in vitro and in vivo, in the context of multiple cancer types, primarily through VEGF 
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(43, 44).  Nicotine has also been reported to enhance migration and invasion of lung, 
pancreatic, and breast cancer cells in vitro, and the metastasis of lung and pancreatic tumors in 
vivo; processes which ultimately lead to mortality of patients (45).  Prior to metastasizing, cells 
are thought to undergo epithelial-mesenchymal transition (EMT), leading to the cells acquiring a 
more mesenchymal phenotype enabling them to more easily escape the primary tumor site, 
survive in the vasculature, and reach distal organs to recolonize as metastatic tumors (45).  This 
process is also thought to be enhanced by nicotine as it acts to induce mesenchymal markers 
and phenotypes, while suppressing epithelial markers and phenotypes (46).   
In addition to these effects, nicotine has been implicated in chemoresistance and survival of 
cancer cells.  This is largely in part through inhibiting apoptotic pathways which will be 
discussed later, conferring a survival advantage to the cells; and also by impacting drug 
metabolism (47, 48). Tobacco smoke itself is known to alter drug metabolism through the 
polycyclic aromatic hydrocarbons (PAHs) present in tobacco, which induce key drug 
metabolizing enzymes which results in higher clearance of cancer therapeutic agents including 
erlotinib, gemcitabine, and taxanes (48, 49).  In animal studies, nicotine has been found to 
induce similar drug metabolizing enzymes as PAHs; however, whether this occurs in humans in 
yet unknown (48).  Interestingly, the enzyme CYP2A6 which is responsible for the metabolic 
inactivation of nicotine into cotinine is induced by tobacco smoke and possibly nicotine itself; 
polymorphisms in the CYP2A6 gene may correlate with lung cancer incidence and nicotine 
dependence (50).  This raises the intriguing possibility that when CYP2A6 is enhanced in 
response to smoking, not only are therapeutic agents cleared more readily but nicotine is also 
metabolized at a faster rate resulting in the patient’s need to smoke greater numbers of 
cigarettes to maintain the nicotine in their bloodstream, thus increasing the likelihood of lung 
cancer incidence. 
More recently, nicotine has been shown to enhance stemness in a subset cancer cells known 
as cancer stem cells (CSCs) in lung, breast, head and neck, and pancreatic cancers (51-53) 
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(54-57). Tumors are traditionally thought to be a disease of clonal origin where a single 
transformed cell has the ability to partially differentiate into heterogenous tumor cell populations, 
thereby initiating and maintaining the tumor.  More recently, growing evidence supports the 
cancer stem cell model which indicates that CSCs arise through a reprogramming mechanism 
and these cells are responsible for tumor progression and maintenance (58).  These stem-like 
cells resemble traditional stem cells in that they are able to self-renew, divide asymmetrically, 
and are slow cycling (59), and have been implicated not only in tumor initiation, progression, 
and maintenance, but also in therapeutic resistance, dormancy, recurrence, and metastasis (59-
61).  Given these properties, understanding and targeting CSCs has become a promising area 
of cancer research with the concept being that targeting this resistant population in addition to 
the tumor bulk would be necessary for the complete eradication of the tumors.   
Over the past decade or better, CSCs have been characterized and isolated based on specific 
cell surface markers that are differentially expressed in the CSCs.  Various markers such as 
aldehyde dehydrogenase 1 (ALDH) and CD133 positivity are commonly used for cancers such 
as breast, colon, brain, pancreas, head and neck (62-65).  For cancer types with no ubiquitously 
expressed marker, a side-population (SP) phenotype has been used to isolate stem-like cells. 
Side-population phenotype is displayed by a subset of tumor cells based on their ability to efflux 
Hoechst 33342 dye out of their nuclei; this is due to the expression of the ABCG2 drug 
transporter on the cell membrane. Stem-like cells from multiple cancers have been found to 
express elevated levels of ABCG2, allowing the isolation of these cells by flow cytometry (66-
68). Nicotine has been found to enhance stem-like properties including self-renewal and 
expression of stem cell genes in CSCs of multiple cancer types, via mechanisms to be 
discussed later in the chapter. 
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Figure 1.1. Tumor Promoting Effects of Nicotine.  Nicotine, while not a carcinogen itself, has been shown 
to enhance a number of tumor promoting properties including proliferation, angiogenesis, EMT, migration, 
invasion, and stemness in vitro.  
 
Nicotinic Acetylcholine Receptors 
The mechanism by which nicotine exerts its tumor promoting functions is through the binding to 
and activation of cell surface receptors, specifically nicotinic acetylcholine receptors (nAChRs) 
and to a certain extent β-adrenergic receptors (β-ARs) (24, 69-71).  In addition to nicotine, its 
oncogenic derivatives NNK and NNN present in tobacco smoke have also been found to bind to 
and activate nAChRs with high affinity stimulating multiple tumor promoting signaling cascades. 
Unlike nicotine, its two derivatives can exert carcinogenic effects through the binding of these 
receptors as well as by inducing DNA damage in a receptor independent fashion (34, 70, 72, 
73).  Interestingly, while the neurotransmitter acetylcholine (Ach) is the known physiological 
ligand for nAChRs in the cholinergic systems of the body, nicotine, NNN, and NNK can bind 
these receptors with greater affinity than Ach and displace Ach, thereby altering the normal 
functions of the receptors (74). 
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Classically, nAChRs are neuronal proteins that respond to Ach as well as drugs including 
nicotine, and are therefore considered cholinergic (75).  While Ach binds to both nicotinic and 
the related muscarinic acetylcholine receptors, nicotine selectively binds to nicotinic 
acetylcholine receptors alone, giving them their name (75). nAChRs are typically expressed in 
the central and peripheral nervous systems where they function as ligand gated ion channels to 
facilitate signal transduction as well as calcium influx, resulting in the release of 
neutrotransmitters such as γ-aminobutyric acid (GABA), dopamine, serotonin responsible for 
nicotine addiction, and the catecholamines adrenaline and noradrenaline (76, 77).  In the 
sympathetic and parasympathetic components of the peripheral nervous system, nAChRs relay 
signals from pre- to post-synaptic cells and act as the receptors facilitating muscle contraction at 
neuromuscular junctions (77).  More recently, nAChRs have been shown to be expressed on 
non-neuronal cells of epithelial and endothelial origin, including lung cancer cells where they 
mediate the synthesis and release of growth factors, pro-angiogenic factors, and neurotrophic 
factors (13, 44, 70, 71, 78).   
nAChRs are pentamers, comprised of five identical α subunits (α7, α8, or α9) or a combination of 
α and β subunits (α2-α6 or α10 subunits, together with β2-β4 subunits (73, 78).  Depiction of 
nAChR organization is detailed in Figure 1.2.  To date, nine different types of α subunits (α2-α10) 
and three types of β subunits (β2-4) have been cloned and characterized  (77); they preferentially 
bind to (-) nicotine over (+) nicotine with approximately 40 fold higher affinity.  While multiple 
nAChR subunits are expressed on non-neuronal cells, the homomeric α7 nAChR has been 
implicated as the primary receptor facilitating nicotine and NNK mediated cell proliferation (34).  
Interestingly, the expression of the α7 receptor itself has been shown to increase in response to 
nicotine stimulation.  The proliferative effects of nicotine are reversed by the α7 specific 
antagonist, α-bungarotoxin (α-BT), or α-cobratoxin (α-CBT), suggesting that the α7 nAChR or its 
downstream effectors might present a potential target for cancer therapy (22, 44, 70).  In contrast 
to α7 nAChR, the heteromeric α4β2 receptor regulates growth inhibitory responses including the 
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release of GABA, which typically acts as a tumor suppressor in a number of cancers including 
lung cancers (73).  Both nAChR types are upregulated when exposed to chronic nitrosamine or 
nicotine stimulation; however, the inhibitory α4β2 nAChRs are desensitized due to constant high 
affinity stimulation, while the tumor promoting α7 nAChRs are able to remain active to exert their 
biological function.  This is likely due to their lower affinity to these ligands and thus lesser chance 
of desensitization compared to the α4β2 receptors (24, 79).  This may also be one of the reasons 
that nicotine exerts in cancer promoting effects primarily through the α7 receptors. Studies 
demonstrating that stimulation with nicotine or tobacco specific nitrosamines could induce cell 
proliferation through α7 nAChRs utilized concentrations of nicotine ranging from 10nM to 10µM, 
which is similar to the concentration observed in the bloodstream of smokers; the average steady 
state level found in the bloodstream of a heavy smoker is typically 1-2µM and can temporarily 
spike to 10µM or more immediately after smoking (80, 81). 
Additional support for the correlation between nAChRs, smoking, and cancer was obtained from 
genome-wide association studies (GWAS), which identified a lung cancer susceptibility locus on 
chromosome 15q24-25. Polymorphisms in this region correlated with increased risk for lung 
cancer development, nicotine dependence, and number of cigarettes smoked per day (82).  
15q24-25 contains CHRNA3, CHRNA5, and CHRNB4 genes that encode for the α3, α5, and β4 
subunits of nAChRs (83, 84).  The α5 subunit has been implicated as the primary receptor 
involved in smoking addiction, and has more recently been associated with smoking behavioral 
patterns (hung 2008).  Further, a non-synonymous variation in CHRNA5 (D398N) is strongly 
associated with increased lung cancer risk (83). 
While nAChRs are the primary receptors through which nicotine exerts its effects, β-ARs and 
EGFRs are also thought to play a role (73, 85, 86).  It has been suggested that nAChRs might  
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Figure 1.2. Depiction of nAChR Organization.  nAChRs are pentameric receptors spanning the plasma 
membrane, which can be either homomeric or heteromeric in subunit composition.  Homomeric receptors 
have either all α7 or all α9 subunits; while heteromeric receptors can be made up of α2-α6 or α10 in 
combination with β2-β4.  These receptors are classical ligand-gated ion channels, and are activated by 
the binding of Ach and nicotine. 
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functionally network with β-AR and EGFR, and all three receptors frequently co-exist on human 
lung cancer cells, airway endothelial cells, and airway epithelial cells (87)  Nicotine binds to α7 
nAChRs inducing the secretion of growth factors such as EGF, neurotransmitters such as 
adrenaline and noradrenaline, and angiogenic factors such as VEGF (86).  The nicotine 
mediated secretion of EGF via nAChRs results in the transactivation of EGFR, leading to the 
activation of mitogenic and antiapoptotic pathways (70, 88).  Similarly, the nicotine mediated 
release of adrenaline and noradrenaline, which are the physiological ligands for β-AR, leads to 
the binding to and activation of β-AR, which in turn activates proliferative pathways and the 
release of EGF, VEGF, and arachidonic acid, which contribute to the development and 
progression of lung cancer (89).  As mentioned earlier, nicotine and NNK have been shown to 
bind to β-ARs as well, stimulating multiple oncogenic and mitogenic signaling cascades (79, 89, 
90).  This cooperative interplay between these receptor types can be expected to have 
significant mitogenic effects on cells, contributing to the oncogenic process. The interplay 
between the different receptors that respond to nicotine and its derivatives is shown in Figure 
1.3. 
Signaling Cascades Initiated Downstream of nAChRs 
nAChR Mediated Induction of ERK/MAPK 
A number of studies have been conducted to elucidate the molecular mechanisms involved in 
nicotine and nitrosamine mediated cell proliferation, and these have revealed the involvement of 
multiple signaling cascades downstream of the nAChRs; the major pathways are depicted in 
Figure 1.4. 
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Figure 1.3. Cooperative Receptor Crosstalk Upon Nicotine Stimulation.  Components of tobacco smoke 
induce nAChR signaling, which in turn activates additional cell surface receptors such as β-AR and 
EGFR, stimulating tumor promoting signaling cascades.  In addition, upon NNK or nicotine binding, 
nAChRs are activated stimulating the secretion of growth factors such as EGF which activate EGFRs, as 
well as neurotrophic factors such as adrenaline and noradrenaline which bind to and activate β-ARs.  
Upon activation, β-ARs further stimulate secretion of EGF to further transactivate EGFRs.  This receptor 
crosstalk suggests a cooperative interaction that facilitates tobacco induced cancer progression.(24) 
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Figure 1.4. Tobacco Smoke Induced nAChR Signaling.  A schematic representing nAChR signaling 
cascades in lung cancer. NNK and nicotine found in tobacco smoke bind to nAChRs with high affinity and 
induce multiple signaling cascades resulting in cycle progression, proliferation, and survival. Upon 
activation of nAChRs by ligand binding, b-arrestin-1 is recruited to the receptor and is necessary for 
further recruitment of Src kinase, which in turn initiates Raf-1 and PI3K/AKT signaling cascades. NNK and 
nicotine-mediated nAChR activation have also been shown to induce signaling cascades such as 
JAK/STAT and Ras/Raf/MAPK, and decrease the levels of cell-cycle inhibitors such as p16INK4 and 
Cip/Kip proteins. (24) 
 
One signaling cascade that is induced by nAChRs across various cell types is the MAPK cascade, 
which is known to facilitate cell proliferation in a wide variety of tumor types. For example, 
stimulation of SCLC cells with nicotine was found to induce the MAPK cascade in a dose-
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dependent fashion; this was diminished upon treatment with the nAChR inhibitor mecamylamine 
(91).  Similar results were reported in another study on SCLC and NSCLC cells, where 
proliferation was increased and MAPK signaling was activated in response to nAChR stimulation; 
interestingly, this study demonstrated that the ERK2 isoform is specifically activated in response 
to nicotine (92). This activation of ERK2 occurs concomitantly, albeit separately, to the activation 
of PKC, as seen by a combination of western blotting experiments and MAP kinase assays (92). 
Multiple studies done on human and murine lung cancer cells have further demonstrated that 
PKC activity was increased in response to nicotine, and was activated independent of the Ras 
pathway (23, 93).  Additionally, it was demonstrated that nicotine had no apparent effect of the 
levels of the MAPK family members p38 or JNK, or on the MAPK phosphatases PAC1 and MKP-
1, indicating that these had lesser roles in nicotine mediated activation of MAPK signaling (92).  
Comparable to this finding on nicotine stimulation, it was found that stimulation of SCLC cells or 
neuroendocrine cells with the nitrosamine NNK resulted in increased DNA synthesis and 
proliferation, as well as activation of Raf-1 kinase; this activation could be blocked by inhibition of 
PKC or by the α7 nAChR specific antagonist α-BT (94). These results indicate that the observed 
effects were mediated through the α7 receptor, and that PKC acts upstream of Raf-1 in this 
signaling sequence (94).  Additionally, it was found that NNK could induce any type of lung tumor 
including NSCLC through activation of Raf-1 kinase-ERK1/2 cascades in cooperation with PKA-
CREB activation downstream of EGFR and β-AR receptors during crosstalk with nAChRs (95). 
Further, it was demonstrated that NNK stimulation increased the expression of c-Myc protein, 
suggesting that c-Myc is another target upregulated by NNK, probably through the activation of 
the MAPK cascade (94).  A number of additional studies have validated these results, 
demonstrating that nicotine and NNK activate the MAPK cascade to induce cellular proliferation, 
and this can be inhibited by α-BT indicating that this chain of events is mediated specifically by 
the α7 nAChR. This is true for both cancer cells as well as normal cells (71, 88).  
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Activation of Src and the Rb-E2F Pathway via nAChRs 
The above studies collectively demonstrate the ability of nicotine and NNK to induce the MAPK 
signaling cascade through the activation of nAChRs; however, unlike growth factor receptors, 
nAChRs do not possess intrinsic kinase activity (96, 97).  A study designed to understand how 
α7-nAChRs induce MAPK cascade and promote cell proliferation demonstrated that the 
scaffolding protein β-arrestin-1 is recruited to the receptor upon nicotine stimulation and this was 
necessary for activation of Src Kinase (98).  Src family kinases are known to facilitate signaling 
from cell surface receptors that lack intrinsic kinase activity and inhibition or depletion of Src could 
prevent nAChR-mediated downstream signaling as well as cell proliferation (98).  This study 
further demonstrated that the activation of Src upon nAChR stimulation leads to the direct binding 
of the Raf-1 kinase to the Rb tumor suppressor protein, preceding the cyclin-cdk mediated 
inactivation of Rb. In vitro kinase assays showed an increase in the activity of kinases associated 
with cyclins D and E when cells were stimulated with 1µM nicotine; further, ChIP assays showed 
that Rb dissociated from proliferative promoters like Cdc6 and Cdc25A upon nicotine stimulation, 
leading to their expression (98). The binding of Raf-1 to Rb is thought to facilitate the inactivation 
of Rb by cyclins and cdks, and Raf-1-Rb interaction was found to be elevated in NSCLC tumor 
samples compared to adjacent normal tissue, indicating a potential role for this interaction in 
tumorigenesis (98). Indeed, a disruptor of the Rb-Raf-1 interaction was found to prevent the 
nicotine-mediated growth and metastasis of lung and pancreatic tumors in mouse xenograft 
models (99-102). 
Interestingly, a subsequent study showed that stable depletion of β-arrestin-1 using shRNA 
resulted in decreased NSCLC cell proliferation with a corresponding decrease in the levels of 
phosphorylated Src kinase and ERK1/2 upon nicotine stimulation compared to control cells, 
indicating a predominant role for β-arrestin-1 in nicotine mediated activation of these signaling 
events (103). The same study investigated the sequence of signaling events induced by nicotine, 
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and it was found that phospho-Src levels were increased within 5 minutes of nicotine stimulation, 
while phospho-AKT1 and phospho-ERK1/2 levels increased after 15 minutes, suggesting that the 
latter two kinases are activated subsequent to Src activation (103).  It was additionally found that 
a subset of β-arrestin-1 molecules can translocate into the nucleus upon nicotine stimulation 
where it physically associates with E2F1; β-arrestin-1 recruited the histone acetyl transferase 
p300 to E2F-regulated proliferative and pro-survival promoters, facilitating histone H3 acetylation 
and gene expression (103). The potential role for β-arrestin-1 in lung tumorigenesis was further 
suggested by the detection of elevated levels of β-arrestin-1 on proliferative promoters in human 
tumor samples compared to adjacent normal tissues. These observations reveal that activation 
of the Rb-E2F cascade is a major consequence of the nAChR mediated signaling events and that 
β-arrestin-1 contributes to this process significantly.  β-arrestin-1 plays a major role in the de-
sensitization of various G-protein coupled receptors; thus, the involvement of β-arrestin-1 also 
suggests an additional functional link between nAChRs and G-protein coupled receptors like β-
ARs and opioid receptors upon exposure to nicotine, which might have a significant impact on the 
growth of lung cancer in smokers. 
Induction of the JAK-STAT Pathway via nAChRs 
In addition to activation of the MAPK and Rb-E2F pathways, it has been reported that nicotine 
stimulation results in the activation of the JAK-STAT signaling pathway and its target genes, which 
are altered in multiple cancer types (104-107).  In a study conducted on oral keratinocytes, 
stimulation of cells with physiologically relevant concentrations of either nicotine or sidestream 
cigarette smoke resulted in increased STAT3 mRNA and protein levels; these levels were 
diminished if the cells were pretreated with the α7 nAChR specific inhibitor α-BT, or if α7 nAChR 
was depleted using siRNA (108).  Further experiments utilizing specific pathway inhibitors 
revealed that the α7-dependent upregulation of STAT3 occurred through activation of the Ras-
Raf-1-MEK-ERK pathway, as well as through the activation of JAK2, indicating the involvement 
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of two complementary pathways (108).  In α7 null mouse cells, nicotine was unable to induce Ras 
mediated activation of STAT3, further demonstrating that this signaling event is mediated through 
the α7 nAChR (108). In a separate study done on NSCLC, stimulation with physiologically 
relevant concentrations of nicotine or NNK resulted in increased phospho-STAT3 levels, leading 
to an induction of the STAT3 target IKBKE (107).  Src kinase is known to activate the JAK-STAT 
pathway in multiple systems, and nicotine was shown to activate Src kinase which in turn activated 
the JAK/STAT pathway signaling in cooperation with MEK/ERK1/2 pathway resulting in increased 
proliferation of pancreatic cancer cells (105).  In the same study, nicotine stimulation resulted in 
increased expression of phospho-JAK2 and enhanced activation of STAT3 through 
phosphorylation at Y705 in a dose dependent manner, while total STAT3 levels remained 
unchanged. These effects were abrogated by treatment with the antagonist α-BT, indicating that 
the signaling was mediated by α7 nAChR (105). Further, nicotine stimulation resulted in an 
ERK1/2 mediated increase in STAT3 phosphorylation at S727, and this could be reversed by 
treatment with an ERK inhibitor (105).  Immunohistochemical staining of tumors from pancreatic 
mouse xenograft studies supported these findings, showing increased phosphorylation of STAT3 
at Y705 in mice exposed to cigarette smoke (105).  Interestingly, similar findings were reported in 
pancreatic cancer cell lines, where nicotine could induce the mucin MUC4 through activation of 
the α7 nAChR, in a Tyk2-Src-ERK dependent manner upstream of STAT1 and E2F1 transcription 
factors (104).  This study showed that nicotine-mediated migration and invasion could be 
abrogated by depletion of MUC4; and that MUC4 gene expression was regulated by STAT1 and 
E2F1 (104).  Upstream of these events, nicotine was reported to increase phosphorylation of 
Tyk2, in addition to increasing the phosphorylation and dimerization of STAT1, elevating its 
transcriptional function in the nucleus (104). Nicotine stimulation was shown to activate STAT3 
via nAChRs as well as β-ARs in bladder cancer cells, leading to overexpression of cyclin D1 
driving cell cycle progression, resulting in reduced sensitivity to chemotherapy; sensitivity could 
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be restored by depletion of STAT3 (109). These studies clearly suggest a role for the JAK-STAT 
pathway in mediating the proliferative functions of nAChRs.  
Upregulation of Cell Cycle Regulatory Molecules  
In addition to inducing multiple mitogenic signaling events, nicotine and nitrosamines have been 
shown to target various components of the cell cycle machinery itself. Numerous studies have 
shown that the expression of cyclins as well as proteins involved in cell cycle checkpoints are 
impacted by nicotine and other components of tobacco smoke. In this context, increased 
expression of cyclin D1 in response to nicotine stimulation has been reported frequently in the 
literature (47, 110, 111).  Initial studies conducted on mouse lung epithelial cells demonstrated 
the ability of nicotine to induce cyclin D1 promoter as well as protein expression through 
nAChR-mediated induction of Ras signaling and activation of its downstream effectors 
Raf/MAPK (112).  It was further demonstrated that Ras activation of c-Jun, which is part of the 
AP-1 transcription factor complex, binds to the cyclin D1 promoter and is necessary for its 
nicotine mediated induction (112). The upregulation of cyclin D1 in response to nicotine was 
shown to occur concomitantly with an increase in Rb phosphorylation and E2F transcriptional 
activity (112), promoting the cell cycle progression of lung epithelial cells. nAChR-mediated 
proliferation via upregulation of cyclin D1 has additionally been reported in mouse pre-
osteoblasts (30). In normal human lung epithelial cells, nicotine and NNK have been shown to 
upregulate cyclin D1 through the ERK1/2 mediated activation of the NFκB, and this signal 
transduction is facilitated via nAChRs (113). Similar results have been reported in human 
NSCLC cells, where nAChR activation by nicotine stimulation led to an induction of cyclin D-
cdk4 and cyclin E-cdk2 kinase activity and Rb phosphorylation, resulting in dissociation of Rb 
from E2F1 and the induction of E2F1 regulated proliferative genes, including Cdc25A and Cdc6 
(47, 111). In addition, nicotine and NNK facilitate cell cycle progression via nAChR and β-AR 
mediated induction of COX2 and prostaglandin E2 (PGE2), with an associated increase in cyclin 
D1 and cdk4/6 expression and Rb phosphorylation (114).  In addition to these cell cycle 
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regulatory molecules, a study on human head and neck squamous cell carcinomas (HNSCC) 
showed that nicotine could enhance the expression of FOXM1 transcription factor, which is 
upregulated in early stages of HNSCC and known to drive cell cycle progression and mitosis; 
and this was found to happen during malignant transformation (115). 
Suppression of Cell Cycle Inhibitors by Nicotine and NNK  
It has been established that components of tobacco smoke can also repress negative regulators 
of cell cycle progression, such as cdk inhibitors (CDKis) (110, 116).   CDKis act to regulate cdk 
activity and are divided into two classes: the INK4 inhibitors including p16, p15, p19, and p18; 
and the Cip/Kip inhibitors including p21 and p27 (110, 116).  Both CDKi types are capable of 
arresting cells in G1 phase by inhibition of cdks, preventing their phosphorylation of Rb and thus 
halting cell cycle progression (110, 116). In human gastric cancer cells, p53, p21, and p27 
expression levels are significantly reduced in response to nicotine or NNK stimulation (114).  In 
NSCLC cell lines, nicotine has been shown to induce the transcriptional repressor, ID1, in a Src 
dependent manner through the α7-nAChR (117).  ID1 is known to induce proliferation by inhibiting 
the transcription of CDKis p16, p21, and p27, preventing their normal growth suppressive effect 
(118).  This data implies that tobacco smoke not only activates components driving cell cycle 
progression, but also inhibits components that arrest cell cycle.   
In addition, it has also been shown in murine and human lung epithelial cells that nicotine acts to 
compromise activation of normal DNA damage checkpoint response at G1/S, but not the G2/M 
checkpoint (119). DNA damage check point is activated after exposure to γ-radiation or the 
tobacco carcinogen benzopyrene , which induces DNA double strand breaks; however, when 
exposed to nicotine, growth restriction was attenuated due to an increase of cyclins D and A, and 
a decrease in the phosphorylation of the checkpoint kinase 2 (Chk2) (119).  Typically ATM and 
ATR protein kinases are activated in response to double or single stranded DNA breaks 
respectively, and they stimulate downstream effectors involved in DNA damage checkpoint 
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response including p53, Chk1, Chk2, and H2AX (116). Activation of these proteins results in cell 
cycle arrest and DNA repair, or if the damage is beyond repair apoptosis will be induced (116).  
Once activated, Chk2 phosphorylates Cdc25A phosphatase, preventing it from 
dephosphorylating and thus activating its target cdk2, resulting in cell cycle arrest (116).  The 
decrease in Chk2 in lung epithelial cells exposed to nicotine suggests that nicotine may be 
capable of overriding DNA damage checkpoint activation, disrupting genetic surveillance and 
increasing the risk of oncogenesis (116, 119).   These studies show that nicotine as well as 
tobacco smoke components can modulate multiple components of the cell cycle machinery, 
facilitating cell cycle progression. 
Regulation of Survival Pathways – Anti-Apoptotic Effects  
While tobacco smoke carcinogens initiate tumors, the current literature raises the possibility that 
nicotine additionally confers a survival advantage to already initiated tumors (47, 120-122) by 
promoting cell cycle progression and by preventing apoptosis (121, 123).  This is of particular 
concern in the context of tobacco smoke components conferring resistance to chemotherapeutic 
drugs (121, 123) as well as radiation (124). Multiple studies have reported that patients who 
smoke demonstrate poor response to cancer chemotherapy, and have worse prognosis than their 
non-smoking counterparts (120, 125, 126). In this context, many attempts have been made to 
elucidate the pro-survival and anti-apoptotic effects of nAChR signaling.  
The PI3K/AKT pathway is a major cancer-associated signaling network that is activated by 
exposure to nicotine and tobacco carcinogens (127-131).  The serine/threonine kinase AKT is a 
known regulator of key cellular processes such as cell cycle progression, as well as cell survival 
(127, 131). Both nicotine and NNK were found to induce AKT phosphorylation at S473 and T308 
in a time and dose dependent manner in normal human bronchial epithelial cells and small airway 
epithelial cells (127).  This effect was evident as early as 5 minutes post nicotine stimulation and 
at a range of physiologically relevant concentrations, from 10nM to 10µM; however, response to 
NNK was not apparent for 15 minutes but was seen at concentrations as low as 1nM (127).  
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Similarly, downstream substrates of AKT involved in cell cycle progression including GSK-3α, 
FKHR, and 4EBP-1 were all induced by nicotine, while GSK3-α and 4EBP-1 were induced by 
NNK (127). Further, this response could be abrogated by the PI3K inhibitor and by the α3/α4 
specific nAChR antagonist DHβE, but not by the α7 specific antagonist α-BT, indicating the AKT 
was being activated through PI3K and this was being facilitated through α3 and α4 containing 
nAChRs (127).   Interestingly, phosphorylated AKT was detected in airway epithelial cells and 
lung tumors from mice treated with NNK, as well as in human lung cancer samples derived from 
smokers (127); similar results were observed in a study conducted on NSCLC and SCLC cells 
(131).  In the latter study, stimulation of cells with physiological concentrations of nicotine and 
NNK  induced activation of AKT as well as its downstream substrates GSK-3, FKHR, tuberin, 
ASK1, 4EBP-1and S6K1; nicotine additionally induced mTOR and MDM2 (131).  This study 
further demonstrated nicotine and NNK could induce proliferation of wild type cells, but not cells 
transduced with a mutant AKT, indicating that the proliferation seen in response to these tobacco 
components is AKT dependent (131).  
In this context, a direct link between activation of PI3K/AKT pathway by nicotine and induction of 
chemoresistance has been proposed. Exposure of multiple NSCLC cells to 1µM nicotine 
conferred resistance to apoptosis induced by cisplatin, gemcitabine and taxol (47). It was found 
that exposure to nicotine led to an increase in the levels of inhibitor of apoptosis proteins (IAPs) 
XIAP and survivin in a α3β4 nAChR dependent manner, downstream of AKT signaling (47, 121); 
interestingly, nicotine did not induce cIAP1 or cIAP2 (47). AKT mediated phosphorylation is known 
to prevent the ubiquitination and degradation of XIAP (132); reduced ubiquitination and 
stabilization of XIAP was observed upon nicotine stimulation, correlating with reduced apoptosis 
(133). Further, induction of survivin by nicotine occurred at the transcriptional level in an E2F1-
dependent fashion, suggesting that exposure to nicotine can confer resistance to apoptosis 
through multiple mechanisms (47).  NFκB transcription factor is induced by nicotine and 
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nitrosamines, promoting cell survival.  Nicotine has been shown to induce NFκB via the MAPK 
pathway, promoting anti-apoptotic functions in mesothelioma cells, mesothelial cells, normal 
bronchial airway cells, and small airway epithelial cells (113, 134).  Similarly, nicotine was shown 
to confer a survival advantage to NSCLC and SCLC cells treated with paclitaxel, and this occurred 
with a concomitant increase in NFκB levels. This study also showed that the ability of nicotine to 
promote survival was dependent on NFκB, which was activated downstream of AKT (131).  In 
normal human bronchial epithelial cells, NNK was found to induce nuclear translocation of NFκB 
and increase its DNA binding activity within 5 to 10 minutes of stimulation, reaching maximal 
activation within 30 minutes (113).  It was further demonstrated that the activation of NFκB 
occurred through the degradation of its negative regulator IκBα, mediated through ERK1/2 
phosphorylation of IκBα (113).  In colon cancer cells, NNK has been shown to induce NFκB in 
association with proliferation, specifically the p65/RelA subunit, with a concomitant decrease in 
IκB, which is known to have inverse correlation to NFκB levels (135). These results strongly 
suggest that nAChR stimulation enhances NFκB activity by targeting IκBα for degradation.  
Additional survival pathways have also been reported to be induced by nicotine. For example, 
nicotine was reported to induce autophagy in colon cancer cells through activation of α7 nAChR 
upstream of PI3K, which resulted in increased levels of Cox2 and PGE2 (136).  Conversely, 
another study found that nicotine could impair autophagy in normal human bronchial epithelial 
cells (137).  The discrepancy between these two papers could be due to differences in cell types 
studied or due to the concentration of nicotine used, as the study done on bronchial epithelial 
cells used 5mM of nicotine, which is highly concentrated compared to the study done in colon 
cancer cells.  There is limited literature available on the impact of nicotine on autophagy, and 
further study is warranted.  Additionally, nicotine stimulation could modulate the levels of Bcl-2 
family of anti-apoptotic proteins (138).  In SCLC cells, nicotine exerts a protective effect against 
apoptosis induced by cisplatin by inducing the activation of Bcl-2 (121); additionally, nicotine 
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exposure results in the phosphorylation and inactivation of the proapoptotic proteins Bax and Bad, 
suppressing cell death (47, 138).  This inactivation is mediated by the induction of PKC, PKA, 
MEK, and P13K signaling cascades (139).  
In addition, components of the TGF-β signaling cascade are modulated by nicotine to promote 
survival. It was found that exposure of NSCLC cells and immortalized bronchial epithelial cells to 
nicotine decreased the expression of SMAD3, resulting in reduced TGF-β mediated growth 
inhibition (140).  Simultaneously, levels of anti-apoptotic Bcl-2 were increased, resulting in 
increased cell viability and reduced apoptosis.  Interestingly, SMAD3 levels were lower in tumor 
samples from current smokers compared to never-smokers, and withdrawal of smoking reduced 
SMAD3 levels (140).  Another study conducted on NSCLC cells showed that long-term exposure 
to nicotine resulted in increased half-maximal inhibitory concentration (IC50) of carboplatin (141).  
This increase in IC50 was associated with elevated Bcl-2 expression and decreased SMAD3 levels 
(141); the sensitivity to carboplatin was dependent upon this reciprocal relationship (141).  
Studies done on pancreatic cancer have also reported the ability of nicotine to confer survival 
advantage to cells and confer resistance to chemotherapeutic agents.  Nicotine was reported to 
increase proliferation and migration on pancreatic ducal adenocarcinoma cells through the 
induction of Src kinase and subsequently ID-1 transcription factor, resulting in increased 
resistance to gemcitabine in vitro (122).  Depletion of Src or ID-1 resulted in diminished ability of 
nicotine to confer resistance to gemcitabine in these cells.  It was further demonstrated that 
nicotine conferred resistance to gemcitabine in mouse pancreatic xenograft models, confirming 
this contention in vivo (122). These studies clearly show that exposure to nicotine and activation 
of nAChR signaling not only promotes the proliferative capacity of lung cancer cells, but also 
renders them resistant to various apoptotic signals and chemotherapeutic agents. 
Additional Tumor-Promoting Functions of nAChRs: EMT, Angiogenesis, and Stemness 
Nicotine and nAChRs have been found to affect multiple steps in the growth and metastasis of 
cancers. nAChRs were found to promote the invasion and migration of cells derived from tumors 
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of the breast, pancreas or the lungs (142).  Nicotine has been found to be a strong inducer of 
angiogenesis and epithelial-mesenchymal transition (EMT), both thought to be precursor steps to 
cells migrating out of the primary tumor site to metastasize to distal organs.  Multiple studies have 
demonstrated the ability of nicotine to enhance endothelial cell recruitment and new vessel 
formation, primarily through stimulating increased VEGF and FGF secretion (23, 143, 144).  
Inhibition of α7 nAChR using a general nAChR antagonist hexamethonium bromide, or the α7 
specific antagonist α-BT could reverse this effect, suggesting nicotine induces angiogenesis 
through these receptors (43, 44, 144).  Our lab has shown that depletion of ID1 transcription factor 
resulted in the inability of human microvascular endothelial cells from the lung to form angiogenic 
tubules, and this occurred downstream of Src kinase, through α7-nAChRs (46).  Interestingly, Src 
was found to be necessary for nicotine-mediated angiogenic tubule formation by human 
microvascular endothelial cells of the lung, but not VEGF induced tubule formation (44).  Nicotine 
has additionally been shown to induce Raf-1 kinase-Rb interaction facilitating angiogenic tubule 
formation in vitro, and that disruption of this interaction could abrogate this effect (44).Nicotine 
stimulation could further mimic exposure to hypoxia, by increasing accumulation of HIF-1α and 
VEGF proteins, resulting in increased angiogenesis (145, 146).  
In addition to angiogenesis, nicotine has been show to enhance EMT.  Our lab has demonstrated 
that nicotine disrupts tight junctions and alters cell morphology to a more mesenchymal 
phenotype, facilitating EMT and invasion (21), and this occurred through β-arrestin-1 but not β-
arrestin-2 (46).  Further, nicotine could suppress expression of epithelial marker E-cadherin, tight 
junction protein ZO-1, as well as membranous β-catenin, while inducing mesenchymal proteins 
vimentin and fibronectin in both lung and breast cancer cells lines (21).  It was further shown that 
nicotine-mediated induction of vimentin and fibronectin, and additionally ZEB1 and ZEB2, 
occurred through β-arrestin-1 mediated regulation of E2F1 transcription factor in the nucleus 
downstream of Src kinase in NSCLC; and cells lacking β-arrestin-1 had diminished ability to 
metastasize in a murine orthotopic lung implantation model (46).  Further, ID1 transcription factor, 
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which is induced by nicotine and plays a role in angiogenic tubule formation, could also induce 
expression of vimentin and fibronectin by downregulating the zinc finger repressor protein ZBP-
89 (86).  
Another mechanism by which nicotine promotes metastasis is by upregulating the expression of 
matrix metalloproteinases, including MMP9, MMP14 and MMP15; this occurred in an E2F1 
dependent manner.  (147).  E2F1 was found to bind to and induce expression of MMP9, MMP14, 
and MMP15 gene promoters which occurred downstream of Raf-1 kinase mediated 
phosphorylation of Rb, releasing E2F1 from Rb, allowing it to transcriptionally induce these 
promoters (147).  This result could be abrogated by disruption of the Rb-Raf-1 interaction through 
use of a small molecule inhibitor in vitro, and treatment with this inhibitor also resulted in reduced 
metastasis of NSCLC tumor cells in vivo (147). 
It has also been proposed that nicotine and nAChRs can contribute to stem-like functions of tumor 
initiating cells, by inducing embryonic stem cell transcription factors including Oct4 and Nanog 
(56, 57). Nicotine treatment also enhanced the expression of CD44 and BMI-1, and promoted the 
sphere formation capacity of squamous cell carcinoma cells (56).  It has been reported that 
nicotine enhances ALDH1+ cell populations in oral squamous cell carcinomas as well as normal 
gingival cells, with a concomitant increase in self-renewal, stemness gene signatures, and EMT 
markers (57).  Similarly, in MCF7 breast cancer cells, nicotine increases CSC populations as 
indicated by an increase in ALDH1+ cells in a dose dependent manner, through activation of PKC 
and Notch; an effect which could be abrogated by α-BT indicating this process likely occurs 
through α7 nAChRs (55).  Later studies reported that nicotine enhances breast cancer SP cells 
as well, through an α9 nAChR-STAT3-galectin-3 mechanism (53). 
In pancreatic cancer, nicotine stimulation results in acquisition of gene expression and functional 
characteristics of CSCs and can induce de-differentiation of acinar cells which frequently give rise 
to metaplasia (54).  Further, nicotine stimulation results in enhanced secretion of the 
neurotransmitters epinephrine and norepinephrine as well as Sonic Hedgehog (SHH), and 
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reduced secretion of the inhibitory neurotransmitter GABA with a concomitant increase in self-
renewal; these pancreatic CSCs were also reported to express α3, α4, α5, and α7 nAChRs, and 
their expression increased in response to nicotine (52).  Our lab has also demonstrated the ability 
of nicotine to promote the self-renewal of stem-like SP cells from NSCLC through the induction of 
stem cell factor (SCF/c-Kit ligand), and the expression of SCF strongly differentiated smokers 
from non-smokers and correlated with poor prognosis (51).  The E2F1 transcription factor could 
induce expression of SCF at the transcriptional level, and depletion of E2F1 or β-arrestin-1 
resulted in diminished ability of nicotine to induce self-renewal in sphere formation assays (51). 
Further, nicotine could increase secretion of SCF and neutralizing antibodies to SCF also 
diminished the ability of nicotine to induce self-renewal (51).  Overall this data suggests that 
nicotine induces self-renewal of SP cells through increased expression of SCF in a β-arrestin-
1/E2F1 dependent manner. 
In addition to nicotine, cigarette smoke condensate has also been found to enhance SP cell 
populations in both lung and head and neck cancer cells through a phospho-AKT pathway, which 
was accompanied by an increase in ABCG2 drug transporter (56).  Further, we have recently 
demonstrated that nicotine can enhance NSCLC adenocarcinoma CSC stemness through the 
embryonic stem cell transcription factor, Sox2. While the above studies indicate additional roles 
for nicotine in promoting EMT and stemness, further studies in this direction would be needed to 
obtain a complete picture of these events.   
 
Electronic Cigarettes: A Gap in the Knowledge 
While the effects of nicotine and its derivatives in tobacco smoke are well documented, the use 
of electronic cigarettes, or e-cigarettes, has emerged as a healthier alternative to traditional 
cigarette smoking; however, due to lack of scientific evidence on short or long term health effects 
associated with their use, this remains controversial (11, 148).  While e-cigarettes do not contain 
tobacco and the multiple classes of carcinogens found in tobacco, they do still contain nicotine in 
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addition to other components such as propylene glycol, vegetable glycerol, and flavorings (148, 
149).  These devices are typically used by pressing a button which activates and internal heating 
coil which brings the e-liquid containing nicotine to a boil, which is then delivered as a vapor to 
the user (148).  The concentration of nicotine present in e-cigarettes varies by brand and 
container, but is typically represented as percent nicotine by volume (NBV) on the packaging. 
Recent publications have discussed the utility of e-cigarettes for smoking cessation.  While e-
cigarette use is not encouraged for those who have never smoked, it has been argued that they 
may be a healthier alternative to traditional cigarette smoking and can be used as a means to 
attain smoking cessation.  It has been known for over a decade that there are considerable 
benefits to any individual who stops smoking including reduced cancer risk, improved therapeutic 
efficacy in patients with already established cancers, rapid reversal of adverse cardiovascular 
effects, and improved health in multiple other areas (150).  Nicotine replacement agents to aid in 
cessation have been shown to double success rates of quitting smoking, and these agents 
previously included things like transdermal nicotine patches, nicotine gum, and other nicotine 
replacement therapies (150).  While e-cigarettes have been around for roughly ten years, their 
use has just recently been rapidly on the rise (151) and is just now being regulated by the Food 
and Drug Administration (FDA).  Preliminary studies have shown e-cigarettes to be successful 
smoking cessation agents in cancer patients.  In a recent report discussing the use of e-cigarettes 
for lung cancer patients, it is stated that the quality of e-cigarettes and e-liquid has been improving 
and most all constituents are now pharmaceutical grade, most flavorings are food grade, there 
are reduced impurities, no solid particles or carbon monoxide, and there are no harmful 
components present in significant levels with the exception of nicotine (149).  This report further 
details that there is 100 fold less nitrosamine content in electronic compared to traditional 
cigarettes, that e-cigarettes are 20 fold less dangerous (149).  It has also been shown that 
smokers who switch to e-cigarettes show steady improvements in their breathing and respiratory 
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health as indicated by exhaled breath (FeNo) and exhaled carbon monoxide (eCO) normalization 
(152).   
Studies have begun to look at impact of e-cigarettes on gene expression; in nasal epithelial cells 
it was reported that biopsies from e-cigarette users showed decreased expression of a number 
of immune and inflammatory response genes identical to biopsies from traditional cigarette 
smokers; they also had an additional number of unique genes repressed (153).  A recent study 
has reported that e-cigarette aerosol contains oxidants and copper nanoparticles that impact 
normal human lung fibroblasts (154).  Here they report that e-cigarette aerosols containing these 
components could increase mitochondrial reactive oxygen species (mtROS) concomitant with 
reduced OxPhos electron transport chain complex IV subunit, increased nuclear fragmentation, 
and increased levels of IL-8 and IL-6 (154).  This data suggests mitochondrial, genotoxic, and 
inflammatory stresses occur in response to e-cigarette aerosol, which may lead to deleterious 
cellular effects (154).  While e-cigarettes may be safer than traditional cigarettes in certain 
aspects, how nicotine present in e-cigarettes impacts the pathophysiology and health of users 
remains to be elucidated. Further, whether the additional components of the e-liquid might 
abrogate or amplify the effects of nicotine in the context of cancer has not been determined.  In a 
study done to assess the presence or absence of nicotine exposure after e-cigarette use, it was 
found that there was no significant difference in urinary cotinine levels (indicative of metabolized 
nicotine) between e-cigarette users and cigarette smokers, while there was a difference between 
e-cigarette users and healthy non-smokers, demonstrating that e-cigarette users are exposed to 
as much nicotine as cigarette smokers (155). Recently in our lab, we have found that three 
different brands of e-cigarette extracts can enhance a number of tumor promoting properties in a 
manner similar to nicotine alone (Schaal, C. et al., manuscript under preparation). Each of the 
three e-cigarettes could enhance the Sox2 embryonic stem cell transcription factor and self-
renewal of cancer stem-like cells, and could further enhance mesenchymal markers and migration 
of NSCLC cells (Schaal, C. et al, manuscript under preparation).  Additionally, stimulation with e-
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cigarette extracts resulted in increased expression of the α7 nAChR, the receptor primarily 
responsible for facilitating nicotine-mediated tumor progression.  Few studies have been 
conducted regarding the effects of e-cigarettes at the molecular level specifically in the context of 
cancer, and this warrants further study which we can expect to be already underway.    
Conclusions 
While nicotine itself is not a carcinogen, it has been found to promote a wide variety of tumor-
promoting properties, almost in a pleiotropic manner, in a number of cancer types.  Once tumors 
are initiated by carcinogens like the nicotine-derivative nitrosamines NNK and NNN, nicotine 
acts to enhance multiple stages of tumor progression from proliferation, angiogenesis, 
chemoresistance, and survival of primary tumors, to EMT, migration, and invasion leading to 
tumor metastasis.  More recently, it has been shown that nicotine enhances the self-renewal of 
cancer stem-like cells, which are implicated in every stage of tumor initiation and progression, 
and are thought to be resistant to therapies, can remain dormant, and result in recurrence and 
dissemination.  In the context of patients who smoke and whose cancers were initiated as a 
result of smoking, targeting pathways which nicotine utilizes to exert its tumor-promoting 
functions seems to hold promise for therapeutic efficacy.  Elucidating these pathways and how 
to target them is therefore, of keen importance.  The primary mechanism by which nicotine 
exerts its effect is through the binding to and activation of α7 nAChRs and the subsequent 
activation of downstream signaling events.  How α7 nAChR is regulated is not well understood.  
Here we elucidate a mechanism by which nicotine itself induces expression of α7 nAChR, 
through E2F1 and STAT1 transcription factors in NSCLC.  Additionally, little is known regarding 
the molecular mechanism underlying nicotine-mediated promotion of cancer stem-like cell 
phenotypes and gene expression.  Here we demonstrate that nicotine can upregulate the 
expression of Sox2 transcription factor which is critical for the maintenance of CSCs in NSCLC, 
and the mechanism through which this occurs. We believe that these studies fill a gap in our 
30 
 
understanding of nicotine function and how nicotine affects the biology of NSCLC cells exposed 
to this agent. 
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CHAPTER TWO: 
MATERIALS AND METHODS 
Kaplan Meier Survival Plots 
 The Kaplan Meier survival curves were generated using KM-plotter online analysis tool 
(http://kmplot.com/analysis), which has previously been described in detail (156-158).  KM-
plotter is a meta-analysis based method of assessing biomarkers in breast, ovarian, lung, and 
gastric cancers using data derived from publicly available microarray databases GEO (Gene 
Expression Omnibus), TCGA (The Cancer Genome Atlas), and EGA (European Genome-
phenome Atlas).  To date, it is capable of assessing the effect of 54,675 Affymetrix gene-chips 
on survival outcome using 10,888 patient samples; including 2,437 lung cancer cases.  For our 
analysis, parameters were set using the 2015 version of the analysis tool, univariate cox 
regression analysis was used, and biased arrays were excluded.  Gene symbols CHRNA7, 
CHRNA3, and CHRNA5 were assessed in NSCLC for all histological subtypes, smoking status, 
and gender differences.  Gene expression which correlated with survival with a p value <0.05 
was considered statistically significant. 
Cell Lines 
Human non-small cell lung adenocarcinoma cell lines A549, H460, and H1650 were obtained 
from the American Type Culture Collection (ATCC).  A549 cells were maintained in Ham’s F12K 
medium (Cellgro, Mediatech, Inc.) supplemented with 10% fetal bovine serum (Atlas 
Biologicals), and H460 as well as H1650 cells were maintained in RPMI 1640 (Gibco, Life 
Technologies, Thermo Fisher Scientific Inc.) containing 10% fetal bovine serum.  Normal human 
bone marrow derived mesenchymal stem cells (hMSCs) were purchased from Lonza and 
maintained in their mesenchymal stem cell basal growth medium (MSCGM) designed to 
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maintain these cells in a proliferative but not differentiated state.  A549 and H1650 cell lines 
have been validated by ATCC and subsequently by Moffitt Core Facilities by STR analysis.  
Primary human mesenchymal stem cells (hMSCs) were pre-validated by Lonza, and were only 
used up to passage 10.   
Generation of Stable Cell Lines 
A549 cell line was used for generating stable overexpression cells.  The overexpression of 
Sox2-core-luc and YAP1 (Addgene #15682) expression plasmids was achieved transfecting 
these plasmids using FugeneHD reagent transfection (Promega) per manufacturer’s protocol, in 
addition to pCDNA2 vector containing G418 selection marker per manufacturer’s instructions. 
The transfected cells were selected using G418 and maintained in Ham’s F12K medium, single 
colonies were selected and expanded for use in experiments.   
Nicotine, E-cigarettes, and Inhibitor Studies 
(-)-nicotine (N3876; Sigma-Aldrich) or e-cigarettes (local stores) were used in these studies.  
A549, H460, or H1650 cells were rendered quiescent by serum starvation in media containing 
0.1% fetal bovine serum for 24 hours, following which cells were stimulated with 1.5µM or 2µM 
nicotine (which are the  physiologically relevant concentrations detected in the bloodstream of 
smokers (hukkanen pharmological reviews 2005) or e-cigarette extracts for the indicated time 
points.  For studies using nicotine or e-cigarette extracts in hMSCs, cells were not serum 
starved but were stimulated with 2µM nicotine or e-cigarette extracts 24 hours after plating, for 
indicated time points.  For studies using signal transduction inhibitors/anti-cancer drugs, cells 
were rendered quiescent by serum starvation for 24 hours, were treated with inhibitors for 30 
minutes, and then stimulated with 2µM nicotine in the presence or absence of inhibitors.  The 
inhibitors used were AZD0530/Saracatinib (Sellekchem) at 10µM, NVP-BKM120/Buparsilib 
(Chemietek) at 20µM, GSK1120212/Trametinib (Chemietek) at 10µM, LEE001/Ribociclib  
(Chemietek) at 20µM, RRD251 at 10µM, α-bungarotoxin (Sigma) at 10µM, or visudyne (Sigma) 
at 2µM. 
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Three different brands of e-cigarettes were used to demonstrate the effects observed were not 
specific to just one type; these included Fin, Njoy, and Mistic (which will be referred to as E-cig 
1, E-cig2, or E-cig3, respectively).  E-cigarette liquid was obtained through extraction of an 
internal liquid-soaked sponge within the devices for E-cig 1 and 2, or by syringe extraction for E-
cig 3.  E-cig 1, 2, and extracts were 1.6% nicotine by volume (NBV) or 16mg/ml, 1.5% NBV or 
15mg/ml, and 1.8% NBV or 18mg/ml respectively as indicated on the manufacturer’s packaging.  
Molarity of extracts from each brand was calculated based on the molecular weight of nicotine 
of 162.23, and the working concentration of 2µM was achieved by serial dilutions of 1:10, 1:9, or 
1:11 for E-cig 1, 2, or 3 respectively, to achieve 10mM, then diluted 1:100 to achieve 100µM, 
and 1:75 for a final concentration of 1.5uM or diluted 1:50 for a final concentration of 2µM. 
siRNAs and Antibodies 
siRNAs used were purchased from Santa Cruz Biotechnology including Oct3/4 (sc036123), 
TEF4/Tead2 (sc45232), α7 nAChR (sc42532), E2F1 (sc29297), STAT1 (sc44123), c-Src 
(sc44250), Sox2 (sc38408), Yap1 (sc38637), c-Yes (sc29860), and β-arr-1 (sc29741).  
Antibodies used for western blot against Sox2 (3579s), p-Src (2101s), p-AKT (9018p), pan-AKT 
(C67E7), Oct4 (2750s), p-ERK1/2 (9101s), and total ERK1/2 (9102s) were purchased from Cell 
Signaling Technologies; against c-Src (05-184) from EMD Millipore; against E2F1 (sc251) from 
Santa Cruz Biotechnology; against Yap1 (53-161) from Abnova, α7 nAChR (ab23832 and 
ab10096) from Abcam; and Actin from Sigma Aldrich (A1978).   
Antibodies used for chromatin immunoprecipitation (ChIP) assays included E2F1 (sc193), E2F2 
(sc633), E2F3 (sc879), E2F4 (sc1082), E2F5 (sc999), Rb (sc50), STAT1 p84/p91 (sc346), and 
STAT3 (sc8109) from Santa Cruz Biotechnology; Yap1 (ab56701), H327Kme3 (ab9045), and 
H327Kme1 (ab6002) from Abcam; a rabbit anti-mouse secondary antibody from Pierce was 
used as a negative control IgG.   
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Antibodies used for immunofluorescence included Sox2 (3579s) from Cell Signaling 
Technologies; ZO-1 (339100) from Invitrogen; E2F1 (sc193), Crm1 (sc5595), and e-cadherin 
(sc8426) from Santa Cruz Biotechnology; α7 nAChR (ab10096) Yap1 (ab56701) from Abcam.  
ChIP-PCR Experiments 
Chromatin immunoprecipitation assays were conducted using previously described protocols 
(103, 159). Cells were treated according to experimental parameters; at the time of harvest, 
cells were treated with 37% formaldehyde for 20 minutes at room temperature for cross-linking 
the DNA to the proteins of interest. The cells were scraped, washed in ice-cold PBS, and 
centrifuged at 4,000rpm at 4°C for 5 minutes. Subsequently, the pellet was resuspended in cell 
lysis buffer (44 mM Tris–HCl [pH 8.1], 1% SDS, 1 mM EDTA [pH 8.0]). The cells were sonicated 
thrice for 15 seconds each, with 30 seconds of rest in between. Subsequently, the cell lysates 
were centrifuged at 12,000rpm at 4°C for 15 minutes. The precleared chromatin was diluted with 
ChIP dilution buffer (16 mM Tris–HCl [pH 8.1], 250 mM NaCl, 0.1% SDS, 1% Triton-X-100, 1.2 
mM EDTA) and rotated overnight with primary antibody at a concentration of 25ug/ml. The next 
day, 60 μL of 1:1 protein G-Sepharose was added to the immune complexes, and the mixture 
was rotated at 4°C for three hours. The beads were washed three times with low salt ChIP 
dilution buffer followed by two times with high salt ChIP dilution buffer. The cross-links were 
reversed by incubation at 65°C overnight. DNA was isolated by ethanol precipitation. The 
associated proteins with the DNA were digested with 50 μg Proteinase K at 37°C for 30 
minutes. DNA was purified by phenol chloroform extraction followed by ethanol precipitation. 
Purified DNA was resuspended in 30 μL MilliQ water. Protein binding to promoter DNA was 
assessed using polymerase chain reaction (PCR). Interactions of the proteins with specific 
regions of the α7 promoter were detected by PCR amplification using the following primer 
sequences: α7-F1- 5’-TCGGGTCTGTTTTGTCTGGTT-3’; α7-R1- 
5’CAGAAGCTGCGCTGGGCACTC-3’; α7-F2-5’-GTACCCAGCGCCGGGAGTAC-3’; α7-R2-5’-
GCTCGCGCGCCTTTAAGGAG-3’.   PCR results were quantitated using ImageJ software and 
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are represented as percent of input control as graphical data. Association on the Sox2 promoter 
was assessed using PCR, and the ChIP primer sequences are as follows: F1-5’-
GAAAAGGCGTGTGGTGTGAC3-3’; R1-5’- CGCTGATTGGTCGCTAGAAAC -3’; F2-5’-
GGGAGTGCTGTGGATGAGC-3’; R2-5’-GTGGGTAAACAGCACTAAGACTACGTG-3’; F3-5’-
TGTGCGCTGCCTGCACCTGTG-3’; R3-5’-ACTCCAGCAGAACCAGCCCTG-3’; F4-5’-
ACGTGCTGCCATTGCCCTC-3’; R4-5’-CGGGTTAGAGGAGGATGAGA-3’. 
Transient Transfections and Luciferase Assays 
A549, H460, or H1650 cells were cultured to 70% confluency and transfected in Opti-MEM 
medium (Gibco, Life Technologies) using Fugene HD (Promega) transfection reagent following 
the manufacturer’s protocol.  The 235bp and 1115bp α7-luciferase gene promoter constructs 
were kindly provided by Dr. Sherry Leonard (University of Colorado, Denver, CO).  Sox2-core-
luciferase was kindly provided by Dr. Angel G. Martin (InBiomed, Spain). The mutSox2-core-luc 
construct containing a mutated Oct4 binding site was previously generated in our lab using 
Quikchange Lightening multi-site-directed mutagenesis kit (Agilent Technologies). The predicted 
binding site of Oct4 in the Sox2-core-luciferase was ATGCAAAA at position -95 to -102.  The 
sequence ATGC from position -99 to -102 was deleted to abrogate the binding of Oct4 to Sox2-
core-luciferase (Borasinghal).  The expression vectors used were pcDNA3-HA-E2F1, pcDNA3-
E2F2, pcDNA3-E2F3, pcDNA3-E2F4, pcDNA3-E2F5, pcDNA3-STAT1, pcDNA3-STAT3, Yap1 
(Addgene #18978).  Empty vector pcDNA3 was used as a control.  Luciferase assays were 
conducted 24 to 48 hours after transfection per manufacturer’s protocol using the Dual 
Luciferase Assay system (Promega).   Results are reported as relative luciferase activity (RLA) 
based on the ratio of RLUs1 firefly luciferase to RLUs2 Renilla luciferase (normalization control) 
values as measured on a Turner Biosystems luminometer. 
siRNA Transfections and  Quantitative Real-Time PCR 
A549 or H460 cells were grown to 70% confluency and transfected in Opti-MEM (Gibco Life 
Technologies) with 100pmol of siRNAs using Oligofectamine reagent (Invitrogen) per 
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manufacturer’s protocol.  4-6 hours after transfection, media was replaced by complete medium 
containing 10% FBS.  RNA was isolated using Qiagen RNEasy miniprep kit (Hilden, Germany) 
according to manufacturer’s protocol.  First strand cDNA was synthesized using Bio-Rad iScript 
cDNA synthesis kit (Hercules, CA).  mRNA expression was assessed using quantitative real-
time PCR (qRT-PCR)( Bio-Rad CFX96 Real Time System) and data were analyzed using the 
CFX96 software.  RT-primers used were as follows:   
α7(F)5’-TCCTGCACGTGTCCCT-3’;  
α7(R)5’-CTTGGTTCTTCTCATCCACG-3’;  
GAPDH(F)5’-GGTGGTCTCCTCTGACTTCAACA-3’; 
 GAPDH(R)5’-GTTGCTGTAGCCAAATTCGTTGT-3’. 
 Vimentin(F)5’-GGACCAGCTAACCAACGACA-3’; 
 Vimentin(R)5’-AAGGTCAAGACGTGCCAGAG-3’; 
 Fibronectin(F)5’-TAGATGTACAGGCTGACAGA-3’; 
 Fibronection(R)5’-TCTTTCTTAAGCCCTTTGCT-3’; 
Yap1(F)5’- CCCAAGACGGCCAACGTGCC-3’; 
Yap1(R) 5’- ACTGGCCTGTCGGGAGTGGG-3’; 
Sox2(F)5’ – GGGAAATGGGAGGGGTGCAAAAGA-3’; 
Sox2(R)5’- TTGCGTGAGTGTGGATGGGATTGG-3’; 
ZEB1(F)5’-AGCAGTGAAAGAGAAGGGAATGC-3’; 
ZEB1(R)5’-GGTCCTCTTCAGGTGCCTCAG-3’; 
ZEB2(F)5’-ATCTGCTCAGAGTCCAATGCAGCAC-3’; 
ZEB2(R)5’-AACAGTATTGTCCACAATCTGTAG-3’. 
Data was normalized using GAPDH as an internal control, and fold change was determined 
using the 2-ΔΔCT method. 
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Lysate Preparation and IP/Western Blotting 
Cells were washed twice with cold 1xPBS, scraped off the plates, collected by  centrifugation for 
5 minutes at 6,000rpm, and lysed in M2 lysis buffer (20mM Tris-HCl pH6.0, 0.5% NP-40, 
250mM NaCl, 3mM EGTA, and 3mM EDTA) containing protease inhibitors as described in our 
previous work (103).  After lysis, protein concentration was measured using Bradford assay 
(BioRad) and equal amounts of proteins were resolved on 8% SDS-page polyacrylamide gels, 
and transferred onto nitrocellulose membranes using BioRad semi-dry transfer unit. Membranes 
were blocked using 5% nonfat dry milk in 1xPBS containing 0.1-0.5% Tween20.  After rinsing 
with 1xPBST, membranes were incubated overnight at 4 degrees Celsius with primary 
antibodies, washed again in 1xPBST, incubated for one hour at room temperature in HRP-
conjugated secondary antibodies at 1:3000 dilutions, and protein was detected using ECL 
reagent from GE Healthcare or Pierce Biotechnology according to standard protocols.  Results 
were quantitated using ImageJ software where protein expression was normalized to the 
corresponding Actin control, and represented as fold change relative to the control as graphical 
data.  
For co-immunoprecipitation assays, 200 μg of total protein lysate from A549 and H1650 
cells were incubated with 4 μg of indicated antibodies.  An equal amount of non-specific IgG 
from rabbit or mouse serum (Sigma-Aldrich) was used as a negative control. The interacting 
proteins were detected by western blotting. 
In-cell Western Blots 
A549 cells were washed three times with PBS, fixed for 20 minutes using 10% buffered 
formalin, permeabilized using 0.2% Triton-x, blocked for 1 hour at room temperature, and 
incubated in primary antibody overnight.  Following primary antibody incubation, cells were 
incubated in rabbit 700cw IRDye (Li-Cor) and mouse 800cw (Li-Cor) secondary antibodies for 1 
hour at room temperature, washed with 1xPBS, and imaged using Li-Cor Odyssey 9120 
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Infrared Imaging System.  Quantitative analysis was conducted using the Odyssey analysis 
software. 
Immunofluorescent Analysis and Confocal Microscopy 
A549  cells were plated onto poly-D-lysine coated  8-well glass chamber slides (LabTek), 
washed three times with PBS, fixed for 20 minutes at room temperature in 10% buffered 
formalin, permeabilized using 0.2% Triton-X 100, blocked for one hour in 5% goat serum, and 
incubated overnight in primary antibody.  Subsequently, cells were incubated in anti-rabbit Alexa 
Fluor-488 or anti-mouse Alexa Fluor-594 secondary antibody (Life Technologies) for 1 hour at 
room temperature, and mounted using DAPI Vectashield (Vector Labratories).   Cells were 
visualized with a DM16000 inverted Leica TCS SP5 tandem scanning confocal microscope at 
630x or 1890x magnification 
Proximity Ligation Assays 
PLA studies were conducted as previously described (160, 161). Cells were fixed using 10% 
buffered formalin and permeabilized with 0.5% Triton-X-100 in PBS for 10 min. The cells were 
blocked with 5% normal goat serum. The diluted primary antibodies were added to the cells and 
incubated at 4oCs overnight. For the remaining steps the Duolink assay system was used 
(Sigma-Aldrich) following the manufacturers’ protocol (161). Briefly, the slides were washed 
twice with buffer A (0.15 M NaCl, 0.02 M Tris, 0.05% Tween 20, pH 7.4) for 5 min. Plus and 
minus PLA probes (secondary antibodies conjugated to oligonucleotides) were added to the 
cells and incubated for 1 h. The cells were washed again in wash buffer A with gentle agitation. 
Amplification was carried out by incubating in the amplification solution with nucleotides and 
fluorescently labeled oligonucleotide detection probes along with polymerase at 37oC for 120 
min. The cells were washed twice in wash buffer B (0.1 M NaCl in 0.2 M Tris, pH7.5) for 10 min. 
The slides were washed with 0.01% wash buffer B in water, dried and mounted in mounting 
medium with DAPI (Vectashield). The images were taken in Leica TCS SP5 confocal 
microscope (Leica Microsystems) at x630 and x1890 magnification. 
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Isolation of SP Cells and Self-Renewal 
SP cells were sorted from heterogenous cell populations using flow cytometry based on 
Hoechst 33342 dye efflux, and were then plated for self-renewal assays using protocols 
described in detail earlier (59, 160). For experiments involving nicotine or e-cigarette extracts, 
these were added directly into stem-cell media at the time of plating post-sort.  For depletion 
experiments, cells were transfected using siRNA and cells were sorted 24 hours later.   
Briefly, asynchronously growing cells were harvested using Accutase reagent (Sigma Aldrich), 
washed once with PBS and re-suspended in DMEM:F12K medium (Gibco, Life Technologies) 
with 2% FBS at 1 x 10^6 cells/ml. Cells were incubated with 4 μg/ml of Hoechst 33342 dye (Life 
Technologies) for 90 min at 37oC in the presence or absence of 1 μM Fumitremorgin C (Sigma 
Aldrich) which is used as a gating control.  Cells were analyzed using LSRII (BD Biosciences) 
and sorted using FACS Vantage (BD FACSDiVa) or Aria (BD FACSAria) cell sorter.  Data 
analysis was conducted by Moffitt Cancer Center’s Flow Cytometry Core Staff using the FlowJo 
software (Tree Star). 
Self-renewal was assessed by sphere formation assay by plating 1,000 sorted SP or MP cells 
per well in stem cell selective media on ultralow attachment 96 well plates (Corning Inc.). Stem 
cell selective media was composed of DMEM/F12K supplemented with 1x N2 supplement 
(Invitrogen), 10ng/ml EGF, and 10ng/ml bFGF (Sigma Aldrich).  Spheres were allowed to grow 
for 10 days; in the experiments utilizing nicotine, fresh nicotine was added after 5 days.  
Spheres were imaged using Evos FL microscope system (Life Technologies). 
Wound Healing Assays 
Wound healing or scratch assays were conducted by plating A549 cells in 6-well plates (BD 
Biosciences) at confluency, and allowed to attach overnight.  Cells were serum starved for 24 
hours prior to making the scratch wounds; the scratch was made using a sterile pipette tip in  
40 
 
each well, each well was washed 1x with PBS, and nicotine and e-cigarette extracts were 
added.  Images were taken every 24 hours for 48 hours, using EVOS FL microscope system 
(Life Technologies) at 10x magnification. 
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CHAPTER THREE: 
NICOTINE-MEDIATED REGULATION OF NACHRS IN NSCLC BY E2F1 AND STAT1 
TRANSCRIPTION FACTORS 
Note to Reader 
Portions of this chapter have been previously published in PLoS One; 11(5); e056451 and have 
been reproduced with permission from PLoS One which is an open access journal, and is 
distributed under the Creative Commons Attribution License.  Author contributions: Schaal, C. 
(writing, design, figures, experiments), Chellappan, S. (writing, concept, and design).  
Abstract 
Cigarette smoking is the major risk factor for non-small cell lung cancer (NSCLC), which 
accounts for 80% of all lung cancers. Nicotine, the addictive component of tobacco smoke, can 
induce proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), angiogenesis, 
and survival in NSCLC cell lines, as well as growth and metastasis of NSCLC in mice. This 
nicotine-mediated tumor progression is facilitated through activation of nicotinic acetylcholine 
receptors (nAChRs), specifically the α7 subunit; however, how the α7 nAChR gene is regulated 
in lung adenocarcinoma is not fully clear.  Here we demonstrate that the α7 nAChR gene 
promoter is differentially regulated by E2F and STAT transcription factors through a competitive 
interplay; E2F1 induces the promoter, while STAT transcription factors repress it by binding to 
an overlapping site at a region -294 through -463bp upstream of the transcription start site.  
Treatment of cells with nicotine induced the mRNA and protein levels of α7 nAChR; this could 
be abrogated by treatment with inhibitors targeting Src, PI3K, MEK, α7 nAChR, CDK4/6 or a 
disruptor of the Rb-Raf-1 interaction.  Further, nicotine –mediated induction of α7 nAChR was 
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reduced when E2F1 was depleted and in contrast elevated when STAT1 was depleted by 
siRNAs. Interestingly, extracts from e-cigarettes, which have recently emerged as healthier 
alternatives to traditional cigarette smoking, can also induce α7 nAChR expression in a manner 
similar to nicotine.    These results suggest an autoregulatory feed-forward loop that induces the 
levels of α7 nAChR upon exposure to nicotine, which enhances the strength of the signal. It can 
be imagined that such an induction of α7 nAChR contributes to the tumor-promoting functions of 
nicotine.  
Introduction  
Genome-wide association studies (GWAS) have identified a susceptibility locus for human lung 
cancer at chromosome 15q24-25, which contains CHRNA3, CHRNA5, and CHRNB4 genes 
encoding the α3, α5, and β4 subunits of nAChRs (82-84).  Polymorphisms in this region were 
found to correlate with nicotine dependence, number of cigarettes smoked per day, and 
increased risk for lung cancer development (82).  The α5 subunit  has been implicated in 
smoking-related lung cancer, implicated as the primary central nervous system receptor 
involved in smoking addiction and behavioral patterns, and additionally has been strongly 
associated with increased lung cancer risk via a nonsynonymous variation in CHRNA5 D398N 
(83, 162, 163).  Methylation status of CHRNB4 has prognostic value for NSCLC, as 
demethylation correlates with tumor progression and poor survival in patients with this disease 
(164).  While multiple nAChRs have been found to be expressed on non-neuronal and NSCLC 
cells, nicotine-mediated tumor progression is facilitated predominantly through the α7 subunit 
(22, 24, 46, 70, 98, 165).  Consistent with this, α7 levels are found to be elevated in mice that 
were administered nicotine, and nicotine-mediated effects on cell proliferation, invasion, 
migration and angiogenic tubule formation are abrogated in the presence of the α7-specific 
inhibitors (22, 122, 166).  Given this information, study of nAChRs and their regulation in tumor 
progression is warranted. While α7 nAChR regulation has been reported to be mediated 
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through Sp1/GATA pathway in squamous cell carcinomas of the lung (33), not much information 
is available on its regulation by other transcription factors or in lung adenocarcinoma. Since 
nicotine is known to activate E2F transcriptional activity, we sought to elucidate whether E2F as 
well as other transcription factors play a role in the regulation of α7 in NSCLC cells, in response 
to exposure to nicotine. 
Mitogenic signaling cascades are aberrantly altered in tumors due to mutations or over 
activation of upstream receptors (167). Our lab had previously shown that in NSCLC, 
stimulation of α7 nAChR with nicotine results in the activation Src kinase through the 
recruitment of the β-arrestin-1 scaffolding protein, followed by the subsequent activation of Raf-
1 kinase which phosphorylates Rb tumor suppressor protein (46, 98, 103).  Upon 
phosphorylation by Raf-1 and cyclins/CDKs, Rb becomes hyperphosphorylated and dissociates 
from E2F transcription factors allowing them to activate expression of E2F target genes, 
including those involved in cell cycle and tumor progression (24, 98).  Upon nicotine stimulation 
the β-arrestin-1 scaffolding protein itself can translocate to the nucleus where it binds to E2F 
transcription factors and increases expression of target genes (46, 103).  The studies presented 
here show how nicotine upregulates the levels of the α7 nAChR subunit through the 
involvement of E2F1 transcription factor, which suggests the existence of a feed-forward 
mechanism by which the downstream signals mediated by nicotine might be amplified. 
Results 
Levels of α3, α5, and α7 nAChRs Correlate with Lung Cancer Patient Survival 
The Kaplan-Meier plotter web-based tool available on KMplot.com was used to analyze a 
database of 2,437 NSCLC patient cases (156) to assess whether patient survival outcome 
correlated with expression of the α7 nAChR subunit which is functionally implicated in lung 
cancer progression, or α3 and α5 nAChR subunits which were identified to correlate with lung 
cancer incidence in GWAS studies (82-84).  Expression threshold was defined by KMplot.com  
using various quantile expression of proposed biomarkers.  High expression of α7 correlated 
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with increased survival across all histological subtypes and variants of NSCLC cases, with a p 
value of 0.00043.  High expression of α3 significantly correlated with decreased survival 
probability in all histological subtypes and variants of NSCLC, with a p value of 0.0015.  
Similarly, high levels of α5 correlated with decreased survival probability across all histological 
subtypes and variants of NSCLC with a p value of 2.6e-09.  This data is shown in Figure 3.1 
 
Figure 3.1. Association of CHRNA7, CHRNA3, and CHRNA5 Expression with Survival Outcome Across 
All Histological Subtypes of NSCLC. 
 
 
When survival outcome and expression of α7, α3, and α5 were analyzed for gender criteria, we 
found that high levels of α7 expression correlated with increased survival while high levels of α3 
and α5 expression correlated with decreased survival in  men (p-values=0.079, 0.012, and 6.1e-
05 respectively); surprisingly, no correlation was found in women. The basis for this difference is 
not clear at this time, but will be discussed later. This data is shown in Figure 3.2. 
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Figure 3.2. Association of CHRNA7, CHRNA3, and CHRNA5 Expression with Survival Outcome Across 
All Histological Subtypes of NSCLC, in Men. 
 
 
NSCLC frequently occurs in patients who are current or former smokers, and nAChRs are 
implicated in smoking-related NSCLC progression (168), so we next analyzed  correlation of 
survival outcome and α7, α3, and α5 expression in male patients who were smokers. High α7 
levels correlated with increased survival in male smokers, while high levels of α3 and α5 
correlated with decreased survival outcome in male patients who smoked (p-value=0.00043, 
0.024, and 0.00069 respectively).  This data is shown in Figure 3.3.  No differences were seen 
when histological subtype or stage were analyzed. 
 
Figure 3.3. Association of CHRNA7, CHRNA3, and CHRNA5 Expression with Survival Outcome Across 
All Histological Subtypes of NSCLC, in Men Who Smoke. 
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Collectively, these data show that high levels of α7 expression correlates with increased survival 
probability, which was unexpected, while α3 and α5 expression correlate with decreased 
survival probability across all histological subtypes of lung cancer, in men, and in men excluding 
never smokers. Here we report that E2F and STAT transcription factors regulate α7 nAChR 
gene expression. 
E2F and STAT Transcription Factors Regulate α7 nAChR Gene Expression 
We first sought to determine whether E2F transcription factors were involved in the activation of 
the promoters of the α3, α5, and α7 genes, since these subunits have been implicated in 
smoking related lung cancer and E2Fs are activated downstream of nAChRs in response to 
nicotine stimulation (82-84).  Genomatix MatInspector analysis of 1000 base pair (bp) regions 
upstream of the transcription start sites (TSS) of each promoter revealed multiple putative E2F 
binding sites including four sites on the α3 promoter, ten sites on the α5 promoter, and nineteen 
sites on the α7 promoter (Figure 3.4).  E2F transcription factors are known to preferentially bind 
the consensus sequence TTTSSCGC (where S is either a C or a G) (169). 
 
Figure 3.4. Analysis of nAChR Gene Promoters Implicated in Lung Cancer.  Schematic representation of 
1000bp promter regions of the α3 nAChR, α5 nAChR, and α7nAChR gene showing potential E2F binding 
sites as black ovals.   
 
During analysis of the α7 promoter, it was noted that there were also two predicted STAT 
transcription factor binding sites which overlapped with two of the predicted E2F sites at regions 
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-337 through -380bp upstream of the TSS (Fig 3.5).  STAT1 transcription factors preferentially 
bind the consensus sequence TTCnnnGAA (170).  This was of interest as we have previously 
found that nicotine stimulation could induce STAT activation thereby activating a number of 
STAT target genes involved in tumor progression.  Interestingly, when we analyzed the α3 and 
α5 nAChR promoter regions 1000bp upstream of TSS, there were no predicted STAT binding 
sites.  Since α7 is the primary subunit facilitating nicotine-mediated tumor progression and was 
found to contain the greatest number of predicted E2F binding sites, we focused our studies 
primarily on this subunit. 
 
Figure 3.5. Predicted E2F and STAT Binding Sites on the α7 nAChR Promoter. Schematic representation 
of 1100bp region of nAChR α7 gene promoter showing potential E2F binding sites as black ovals and 
potential STAT binding sites as green ovals.  Arrows represent the position of primers spanning E2F and 
STAT binding sites used for ChIP assays.  Sequence data of overlapping E2F and STAT binding sites is 
detailed. 
 
To validate whether E2F and STAT transcription factors could bind to the α7 promoter, 
chromatin immunoprecipitation (ChIP) assays were conducted on A549 and H460 cells, both of 
which harbor K-Ras mutations, which frequently occur in lung cancer patients who smoke. It 
was found that E2F1, E2F2, E2F3, E2F4, and E2F5 could bind at region -177 through +13bp  
upstream of TSS, where 10 predicted E2F sites were clustered on the promoter, in both A549 
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and H460 cell lines (Figure 3.6A); quantification of the bands are shown in the bottom panel.  
E2F1 and E2F4 additionally were shown to bind at region -294 through -463bp upstream of the 
TSS in A549 where the two predicted E2F sites overlap with the two predicted STAT sites; and 
E2F1, E2F2, E2F3, E2F4, and E2F5 were shown to bind this site in H460 (Fig 3.6B); the bands 
are quantified in the lower panel.   STAT1 and STAT3 also bound the promoter at region -294 
through -463bp upstream of the TSS where the two predicted STAT sites overlap with two E2F 
sites in A549;  STAT1 but not STAT3  bound to this region in H460 cells (Fig 3.6C); the results 
are quantified in the lower panel.   
 
Figure 3.6. ChIP Analysis of α7 nAChR Promoter. (A) Assays showed binding of E2F1-5 to the α7 nAChR 
promoter region -177 through +13 in A549 cells and binding of E2F1-4 in H460 cells. (B) E2F1 and E2F4, 
and to some extent E2F2 and E2F3 could also bind region -294 through -463 in A549 cells while E2F1-5 
could bind this region in H460cells . (C) STAT1 and STAT3 additionally could bind region -294 through -
463 in A549 cells, while STAT1 alone could bind in H460 cells.  Sonicated DNA was used as input 
control, and there was no detectable amplification from irrelevant IgG, used as negative control.  
Quantification of the data is depicted as percent of input, in the corresponding graphs. 
 
Experiments were conducted to determine whether E2F and STAT transcription factors which 
bound the α7 promoter could regulate its expression.  Transient transfection experiments were 
carried out using an 1115bp α7-luciferase promoter construct which we received from the lab of 
Sherry Leonard at the University of Colorado, Denver (171).  Co-transfection using 0.5µg of the 
reporter construct with 1µg of E2F1, E2F2, E2F3, or E2F4 expression vectors resulted in 5.0, 
5.4, 3.9, or 1.2 fold induction of α7-luciferase expression respectively; conversely co-
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transfection with 1µg of E2F5, STAT1, and STAT3 expression vectors resulted in 70%, 50%, 
and 40% reduction in expression of α7-luciferase reporter in A549 respectively, demonstrating 
the ability of these proteins to differentially regulate the α7-luciferase promoter (Figure 3.7A and 
B).  Similar results were observed in H460 cells where co-transfection of α7-luciferase promoter 
with E2F1, E2F2, or E2F3 resulted in 2.6, 1.7, or 1.4 fold induction respectively; E2F4 had little 
effect on expression at 1.1 fold induction, E2F5, STAT1, and STAT3 resulted in 10%, 60%, and 
40% reduction of expression respectively.  To further assess the role of E2F1 and STAT1 in the 
regulation of α7 promoter, E2F1 or STAT1 were depleted in A549 or H460 cells by transient 
transfection using 100pmol of small interfering RNAs (siRNA) and expression of α7 mRNA was 
assessed using qRT-PCR. α7 mRNA was reduced by 20% in A549 or 30% in H460 upon 
depletion of E2F1, while α7 mRNA levels were increased by 1.5 fold in A549 or 1.2 fold in H460 
upon depletion of STAT1, further suggesting that E2F1 induces α7 expression while STAT1 
represses it (Figure 3.7C and D). 
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Figure 3.7. E2F and STAT Transcription Factors Regulate α7 nAChR Expression. (A and B) Transient 
transfection experiments showing that E2F1-3 can induce the α7 promoter, E2F4 has no effect, and 
E2F5, STAT1, and STAT3 act repress it in A549 and H460 cells.  (C and D)  Depletion of E2F1 by siRNA 
results in reduced expression of α7 mRNA, while depletion of STAT1 results in increased expression in 
A549 and H460 cells. 
 
E2F1 and STAT1 Differentially Regulate α7 nAChR  
Since E2F1 and STAT1 were found to have the greatest effect on α7 expression, we focused on 
these two factors for further studies. The two predicted STAT binding sites overlapped with two 
putative E2F sites in the region -294 through -463bp upstream of the TSS on the α7 promoter; 
so we next sought to determine whether the differential regulation of α7 expression observed 
was occurring via competitive interplay between E2F1 and STAT1 transcription factors binding 
to this region (Figure 3.8A).  Transient transfection experiments were conducted using α7-
luciferase co-transfected with 1µg of E2F1 and increasing concentrations (0.5µg, 1.0µg, and 
2.0µg of STAT1); STAT1 could repress E2F1 mediated induction of α7-luciferase in a dose 
dependent manner (Fig 3.8B).  Reciprocally, 0.5µg, 1.0µg, and 2.0µg of E2F1 could alleviate 
repression mediated by 1µg of STAT1 on α7-luciferase expression in a concentration 
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dependent manner (Fig 3.8C). Thus each transcription factor could abrogate the effect of the 
other, suggesting a competitive interplay occurring at this region of the α7 promoter. 
   
Figure 3.8. E2F and STAT Have Overlapping Binding Sites on the α7 Promoter, and Differentially 
Regulate its Expression. (A) Schematic representation of overlapping E2F1 and STAT1/3 binding sites on 
α7 promoter region -294 through -463. (B and C) Transient transfection show increasing concentrations of 
STAT1 repress E2F1-mediated induction of α7 promoter; reciprocally, increasing concentrations of E2F1 
can alleviate STAT1-mediated repression of α7 promoter in A549 cells. 
 
Additional experiments were conducted to validate these findings. Towards this purpose, site 
directed mutagenesis was conducted.  Nucleotides critical for STAT1 binding on the  α7-
luciferase promoter at position -368, -373, -374, -375, -376, -381, and -382bp upstream of TSS 
were mutated to disrupt STAT1 binding; these sites coincided with the overlapping E2F binding 
site (Figure 3.9A).  Transient transfections were conducted using 0.5µg of α7-luciferase or α7-
luciferase-STAT-mutant promoter constructs with 1µg of E2F1 and STAT1; STAT1 had 
diminished ability to repress α7 when the binding site was mutated (Figure 3.9B).   STAT1 
reduced α7-luciferase promoter activity by 86% and 83% in A549 and H460 cells respectively, 
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while STAT1 reduced α7-luciferase-STAT-mutant promoter activity by 0.02% and 39% in A549 
and H460 cells, respectively. E2F1 could induce α7-luciferase promoter activity 3.1 and 3.7 fold 
in A549 and H460 cells, and could induce the α7-luciferase-STAT-mutant promoter activity 2.3 
and 3.0 fold in A549 and H460 cells, respectively. Further, transient transfections were 
conducted using 0.5µg of a truncated 235bp α7-promoter construct lacking the two STAT 
binding sites (but retaining ten E2F binding sites), or the full length 1115bp α7-promoter 
construct 1µg of STAT1 could repress the 1115bp α7-promoter construct by 70%, while STAT1 
resulted in a 10% repression of the 235bp α7-promoter construct. E2F-mediated induction of 
both the 1115bp and 235bp α7-luciferase promoters remained similar at 2.56 and 2.69 fold 
induction, respectively (Figure 3.9C).  This data suggest that region -294 through -463bp 
upstream of the TSS on the α7 promoter is critical for STAT-mediated repression; E2F1 could 
still induce the promoter, through additional sites close to the TSS.   
 
Figure 3.9. Region -294 Through -463bp Upstream of TSS is Critical for STAT-Mediated Repression of 
α7-luc. (A) Schematic representation of DNA sequence of overlapping E2F and STAT binding sites.  
Nucleotides which were mutated to disrupt STAT binding on α7 promoter are depicted in red on the left 
and the resulting mutated sequence is depicted in red on the right. (B) Transient transfections showed 
that STAT1 could repress the α7 promoter but not the α7-STAT-site-mutant promoter in A549 and H460 
cells. (C) Transient transfection showed that STAT1 could repress the 1115bp α7 promoter, but not 
235bp α7 promoter lacking predicted STAT binding sites. 
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Nicotine and E-cigarette Extracts Enhance α7 nAChR Expression  
Nicotine has been shown to enhance α7 in adenocarcinoma and squamous cell carcinoma of 
the lung in vitro as well as in mouse lung adenocarcinoma models (22, 98, 104, 165). Transient 
transfection experiments were conducted to assess whether nicotine induces the α7 promoter.  
Towards this purpose, A549 and H460 cells were transiently transfected with 1µg of 1115bp α7-
luciferase promoter, serum starved for 24 hours, and stimulated with 2µM nicotine for 24 hours.  
Upon nicotine stimulation, α7-luciferase activity increased by 1.9 and 2.6 fold in A549 and H460 
cell lines respectively, compared to unstimulated cells (Figure 2.10A). Time course experiments 
showed that in A549, mRNA levels of α7 decreased by 50% at 18 hours and 90% at 24 hours, 
but increased at 48, 72, 96 and 120 hours reaching a 5.1 fold increase by 120 hours (Figure 
2.10B, top panel). To determine whether the other nAChRs implicated in lung cancer are also 
impacted by nicotine, α3 and α5 mRNA levels were additionally assessed by qRT-PCR after 18, 
24, 48, 72, or 96 hours of nicotine treatment.  α3 was reduced by 92% and 76% at 18 and 24 
hours, but induced by 2.25 and 6.1 fold by 72 and 96 hours post stimulation (Figure 3.10B, 
middle panel).  α5 levels were shown to increase across all time points of nicotine stimulation, 
ranging from 1.5 to 2 fold (Figure 3.10B, bottom panel). Similar results were observed when 
cells were examined by immunofluorescence followed by confocal microscopy; α7 was 
increased upon nicotine stimulation for 48 hours (Figure 3.10C).  
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Figure 3.10. Nicotine Can Induce α7 Expression by 48 Hours. (A) Transient transfection showed that 2µM 
nicotine could induce the α7 promoter after 48 hours of stimulation in A549 cells. (B) qRT-PCR analysis 
showed that 2µM nicotine induced α7 mRNA levels at 48, 72, 96, and 120 hours, but not at 18 or 24 
hours.  2µM nicotine reduced α3 mRNA expression at 18 and 24 hours, little effect was seen at 48hrs, 
and expression was induced by 72 and 96 hours.  2µM nicotine induced α5 mRNA levels at 18, 24, 48, 
and 96 hour time points. (C) Immunofluorescent staining showed that 2µM nicotine could induce α7 at the 
protein level after 48 hours in A549 cells.   
 
To conduct time course experiments on protein levels, cells were rendered quiescent by serum 
starvation for 24 hours, and stimulated with 2µM nicotine for 18, 24, 48, 72, 96, or 120 hours.  
α7 protein levels were assessed using SDS-page western blot analysis or α7 mRNA expression 
was assessed by qRT-PCR. In A549 cells, α7 protein level increased beginning at 48 hours 
through 120 hours (Figure 3.11A); quantification of the blot is shown in the bottom panel. In 
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H460 cells, α7 protein level increased beginning at 18 hours through 120 hours (Figure 3.11B), 
and the blot is quantified in the bottom panel.  
 
Figure 3.11. Nicotine Induces α7 nAChR in NSCLC. (A) Western blot analysis showed 2µM nicotine 
induced α7 protein levels at 48, 72, 96, and 120 hours; an effect not seen at 18 or 24 hour time points in 
A549 cells.  (B) In H460 cells, 2µM nicotine induced α7 protein levels at 18, 24, 48, 72, 96, and 120 hour 
time points.  Arrows indicate the α7 protein band of interest, at approximately 50 kD.  Quantification of the 
western blot data is depicted in the corresponding graphs. 
 
The health impact and implications of tobacco smoke and nicotine have been well documented; 
however, more recently electronic-cigarettes (e-cigarettes) have emerged as an alternative to 
cigarette smoking (172).  While e-cigarettes are advertised as less harmful tobacco-free 
alternatives that can also be used for smoking cessation, these products still contain nicotine in 
addition to other chemical compounds and their use is currently unregulated (173, 174).  Here 
we examined whether liquid extracts (containing nicotine) from three common brands of e-
cigarettes Fin, Njoy and Mistic, had similar effects as nicotine on α7 nAChR expression.  After 
48 hours of stimulation with e-cigarette liquid, levels of α7 were assessed and were shown to 
increase at 1.5µM concentration.  Western blot analysis and immunofluorescent staining 
demonstrated that 1.5µM of each of e-cigarette extract could enhance α7 at the protein level 
(Figure 3.12A and B).  Western blot results were quantitated and are depicted in Figure 3.12C. 
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Figure 3.12. E-cigarette Extracts can Induce α7 Protein Expression. (A and B) Immunofluorescent 
staining and western blot analysis showed that 1.5µM of e-cigarettes could induce α7 at the protein level 
after 48 hours in A549 cells, to a similar extent as nicotine. (C) For western blot, arrow indicates the α7 
protein band and quantification of the data is depicted in the corresponding graphs. 
 
Transient transfection assays demonstrated 1.5µM of each e-cigarette extract to induce α7-
luciferase promoter activity, as well (Figure 3.13).   
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Figure 3.13.  E-cigarette Extracts Can Induce α7-luciferase Promoter Activity. 1.5µM concentrations of 
extracts from each of the three brands of e-cigarettes could induce α7-luciferase. 
 
At the mRNA level, Fin induced α7 by 2.3 fold, Njoy induced α7 by 3.2 fold, and Mistic induced 
α7 by 2.7 fold (Figure 3.14).  To assess the impact of e-cigarettes on the other nAChRs 
implicated in lung cancer, qRT-PCR analysis was conducted.  α3 mRNA levels were decreased 
after 48 hours of e-cigarette stimulation and α5 mRNA levels were increased after 48 hours of e-
cigarette stimulation, both effects similar to that seen after 48 hours of nicotine stimulation 
(Figure 3.14). 
 
Figure 3.14.  E-cigarette Extracts Impact Expression of α7, α3, and α5 nAChRs at the Transcriptional 
Level.  qRT-PCR analysis showed that 1.5µM of extracts from each of the three brands of e-cigarettes 
resulted in increased α7 mRNA levels after 48 hours, decreased α3 mRNA levels after 24 hours, and 
increased α5 mRNA levels after 48 hours. 
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Nicotine-Mediated Induction of α7 is Abrogated by Inhibition of Src, PI3K, MEK1/2, 
CDK4/6, Rb-Raf Interaction, and α7 nAChR 
To elucidate the mechanism by which nicotine induces α7 expression, experiments were 
conducted using inhibitors to signaling pathways that are activated in response to nicotine 
stimulation.  Previous studies have identified that Src kinase is activated upon nicotine 
stimulation and subsequently activates downstream kinases including PI3K and Raf-1 (24, 175).  
PI3K is classically known to activate AKT/PKB, followed by activation of transcription factors 
such as NFκB, which initiates transcription of a number of tumor promoting genes. Similarly 
upon nAChR activation, Raf-1 and cyclin/CDKs phosphorylate Rb tumor suppressor protein, 
resulting in the induction of E2F-mediated transcription of proliferative genes. Studies have also 
shown that nicotine stimulation activates the MAPK cascade. To elucidate whether these 
pathways are involved in nicotine-mediated induction of α7 expression, cells were stimulated 
with nicotine in the presence or absence of the following inhibitors:  AZD0530/Saracatinib 
targeting Src, BKM120/Buparlisib targeting α, β, δ, and γ isoforms of PI3K, 
GSK1120212/Trametinib targeting MEK1/2, LEE001/Ribociclib targeting CDK4/6, RRD251 
targeting Rb-Raf-1 interaction, and α-bungarotoxin/α-BT, which is an α7 nAChR antagonist.  
Western blot analysis demonstrated all six inhibitors abrogated nicotine-mediate induction of α7 
protein levels, although the Src inhibitor AZD had a modest effect (Figure 3.15A).  These results 
were confirmed at the mRNA level by qRT-PCR, which showed nicotine to induce α7 mRNA 
levels by 1.6 fold, while AZD, BKM, GSK, LEE, RRD, or α-BT reduced α7 levels by 61%, 58%, 
18%, 14%, 15%, and 39%, respectively (Figure 3.15B).  
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Figure 3.15. Nicotine-Mediated Induction of α7 could be Abrogated by Inhibitors of Src, PI3K, MEK, 
CDK4/6, Rb/Raf, or α-BT. (A and B) Western blot and qRT-PCR analysis showed that treatment with 
indicated inhibitors for 30 minutes prior to nicotine stimulation could abrogate the nicotine-mediated 
induction of α7 levels in A549 cells.  For western blots, arrows indicate the α7 protein band. 
   
These results were additionally confirmed by in-cell western blotting which quantitates protein 
levels. 48 hours of nicotine stimulation induced α7 expression 2 fold, while treatment with 
Saracatinib, Buparsilib, GSK, Riboiclib, RRD251, or α-BT 30 minutes prior to nicotine 
stimulation reduced α7 levels by 67%, 32%, 45%, 34%, 34%, and 40%, respectively; 
quantification of signal intensity is included in the right panel (Figure 3.16).   
 
Figure 3.16. Licor In-Cell Western Blot Confirmation of Inhibition. In-cell western analysis further showed 
that treatment with indicated inhibitors for 30 minutes prior to nicotine stimulation could abrogate the 
nicotine-mediated induction of α7 levels in A549 cells.   
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E2F1 is Necessary for Nicotine-Mediated Induction of α7  
Since we find that E2F1 and STAT1 regulate α7 nAChR expression, we sought to determine 
whether the effect of nicotine on α7 occurs through E2F1 and STAT1.  To test this, cells were 
transfected with 1µg of α7-luciferase which increased 2.1 fold upon 48 hours of nicotine 
stimulation, an effect which was reduced by 33% upon E2F1 depletion and increased by 33% 
upon STAT1 depletion in A549; similarly, in H460 cells nicotine increased α7-luciferase 1.7 fold, 
which was reduced by 41% upon E2F1 depletion, and increased by 29% upon STAT1 depletion 
(Figure 3.17A).    This was further confirmed when cells were transfected with small interfering 
RNA (siRNA) to deplete E2F1 or STAT1, and subsequently stimulated for with 2µM of nicotine 
for 48 hours, and α7 levels were assessed.  We found that when E2F1 was depleted there was 
diminished ability of nicotine to induce α7, and when STAT1 was depleted nicotine further 
induced α7-luciferase or α7 at the protein or mRNA level in A549 cells.  At the RNA level, 
nicotine induced α7 by 2.3 fold, which was reduced to by 61% upon E2F1 depletion, and 
increased by 13% upon STAT1 depletion (Figure 3.17B).   
 
Figure 3.17. Nicotine-Mediated Induction of α7 is abrogated by siRNA Depletion of E2F1. (A) Transient 
transfection showed that nicotine-mediated induction of the α7 promoter was decreased when E2F1 was 
depleted using siRNA, but was increased when STAT1 was depleted using siRNA in A549 and H460 
cells. (B) Similar results were seen by qRT-PCR analysis which showed that nicotine-mediated induction 
of α7 mRNA was abrogated when E2F1 was depleted using siRNA, but enhanced when STAT1 was 
depleted using siRNA. 
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Collectively, This data suggests that E2F1 as well as the pathways targeted by inhibitors to Src, 
PI3K, MEK1/2, CDK4/6, RRD251, or α-BT play a role in nicotine-mediated induction of α7 
nAChR, as detailed in the schematic presented in Figure 3.18, and if impeded by inhibition (or 
depletion in the case of E2F1) result in abrogation of nicotine-mediated induction of α7. 
 
Figure 3.18. Schematic Depicting Signaling Cascades Initiated by Nicotine-Mediated Activation of the α7 
nAChR and Inhibitors used to Target these Pathways. Upon nicotine binding to α7 nAChR, oligomeric 
complexes form including the receptor, β-arrestin-1 scaffolding protein, and Src kinase.  This activates 
Src, resulting in activation of Raf-1 kinase which acts along with activated CDK/cyclins to 
hyperphosphorylate the Rb tumor suppressor, resulting in its dissociation from E2F transcription factors, 
allowing them to activate their target genes including a number of genes involved in multiple aspects of 
tumor progression.  The PI3K-AKT and MAPK signaling pathways are also known to be activated by 
nicotine-mediated α7 nAChR activation subsequent to Src phosphorylation; and activation of MEK-ERK is 
known to result in activation of CDK/cyclin complexes.  AKT1 activation downstream of PI3KC in 
response to nicotine has additionally been shown to result in activation of NFκB transcription factors. 
Further, Src activates STAT proteins up nicotine-mediated activation of α7 nAChR.  Inhibitors used in this 
study are depicted in black and white boxes, and their targets are indicated accordingly. 
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Discussion 
Cigarette smoking is highly correlated with NSCLC and accounts for 80-90% of all lung cancer 
deaths (10).  Our lab and others have previously reported that nicotine, while not able to initiate 
tumors itself, can enhance a number of tumor promoting properties (52, 53, 176, 177).  These 
tumor promoting effects have been shown to occur primarily through the binding to and 
activation of nAChRs; and proliferation, migration, invasion, and EMT have been shown to occur 
through the α7 nAChR subunit in specific, implicating it in tumor progression. The α7 nAChR 
subunit is overexpressed on human NSCLC tumors compared to normal adjacent, and nicotine 
can enhance expression of the α7 receptor itself, further demonstrating the importance of α7 in 
nicotine-mediated pathophysiological effects; however, how this occurs and how the α7 nAChR 
gene is regulated is less understood.   
In squamous cell carcinoma of the lung (a subset of NSCLC), it has been previously reported 
that nicotine increases α7 nAChR expression which accelerates tumor growth and results in 
worse clinical outcomes (165).  In this context, nicotine increased α7 expression through 
transcriptional mechanisms involving Sp1 and GATA4/6 proteins.  Nicotine enhances 
association of these proteins to the promoter, and they are required for its nicotine-mediated 
induction.  The transcriptional regulation of the α7 nAChR promoter in the context of 
adenocarcinoma of the lung, as well as the mechanisms by which this occurs, still remains 
elusive.  In this study we demonstrate that E2F1 and STAT1 transcription factors act to 
differentially regulate the α7 gene promoter and disruption of STAT binding sites can enhance 
α7 expression.  Further, we find that nicotine-mediated induction of α7 can be abrogated by 
inhibitors to Src, PI3K, MEK1/2, CDK4/6, Rb-Raf-1 interaction, or α7 nAChR suggesting the 
pathways targeted by these molecules play a role in nicotine-mediated induction of α7 and their 
disruption inhibits this. As depicted in Figure 3.18, stimulation of cells with nicotine activates Src 
via β-arrestin-1, facilitating the downstream signaling events. These signaling events lead to the 
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enhanced expression of α7 nAChR, which in turn amplifies the same signaling cascades.  Our 
earlier studies had shown that signaling via α7 nAChR leads to the expression of genes 
involved in cell  proliferation, like Cdc25, thymidylate synthase and Cdc6 (98); those involved in 
epithelial-mesenchymal transition like ZEB-1 and ZEB2  as well as fibronectin and vimentin (21, 
46, 86) and genes involved in invasion and metastasis, including multiple matrix 
metalloproteinases (24, 147).  Overall, it is highly likely that cells exposed to nicotine for 
extended periods of time will overexpress α7 nAChR, which we had observed in a mouse model 
(22); this will lead to the induction of genes involved in tumor progression and metastasis, thus 
facilitating the tumor promoting functions of nicotine.  
Interestingly, we also demonstrate that increasing amount of one transcription factor could 
abrogate the effect of the other on α7 promoter expression, suggesting a competitive interplay 
between E2F1 and STAT1.  A number of previous studies have reported similar findings of 
competition between transcription factors to differentially regulate gene expression, across 
various contexts. For example, in macrophages it has been shown that AP-1, STAT1, and 
STAT3 compete with NFκB to bind a gene encoding aralkylamine N-acetyltransferase and 
differentially regulate its expression to control the synthesis of melatonin and inflammatory 
response (178).  In colorectal cancers it has been shown that β-catenin/TCF4 complexes 
compete with TCF3 to bind to the MYC promoter, and β-catenin/TCF4 induces its expression 
while TCF3 represses it (179).  HNF4α has also been found to compete with TCF4 and AP-1 at 
overlapping motifs to regulate distinct genes involved in proliferation and inflammation in 
colorectal cancer (180).  Notably, a number of reports of competitive transcription factor 
interplay involve TCF, AP, SP-1, and STAT transcription factors (178-182).  While this suggests 
that such a dynamic to differentially regulate gene expression may be a common mechanism 
occurring in response to environmental stimuli, this is the first demonstration of such a 
mechanism involved in the regulation of nAChR expression.  What determines how E2F1 and 
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STAT1 transcription factors compete to differentially regulate α7 nAChR is unclear at this time.  
It could be time dependent, where STATs repress expression at early time points while E2Fs 
activate expression at later time points.  It could also be context dependent, and environmental 
stimuli may cue which transcription factor mediates expression.  Further studies in this direction 
are warranted.  
Recently, the use of e-cigarettes has emerged as an alternative to traditional cigarette smoking 
and as a smoking cessation agent.  These nicotine-delivery devices represent a public health 
concern, and mounting evidence suggests that the liquid containing nicotine found within the 
cartridge of e-cigarettes, which is delivered as a vapor/aerosol to the user, elicits detrimental 
health effects similar to those of nicotine from traditional cigarettes (148).  There has been an 
increase in their use among both youths and adults (183). Typically, e-cigarettes consist of a 
battery, a heating element, an air flow sensor, and a cartridge containing liquid which includes 
nicotine in addition to other components such as propylene glycol, glycerol, and other additives.  
When activated the liquid is heated and is delivered as an aerosol in a vapor form to the user 
(148).  Each brand varies in concentration of nicotine present in the liquid, but it is typically 
indicated as percent nicotine by volume (NBV) on the packaging of the item.  While e-cigarettes 
are thought to be better than traditional cigarettes since they lack tobacco which is known to 
contain multiple classes of carcinogens, the presence of nicotine may still largely impact 
pathophysiology and health in users.  In this study, we report that e-cigarette extracts could 
induce α7 nAChR levels in a manner similar to nicotine.  Further research is underway to 
elucidate whether these products can also enhance other tumor-promoting properties, and 
whether this occurs through the same mechanisms as nicotine-mediated tumor progression. 
Of interest, our Kaplan Meier analysis revealed that high levels of the CHRNA7 gene encoding 
α7 nAChR correlated with increased patient survival in NSCLC, despite the known role of α7 to 
facilitate tumor progression.  It is unclear why this is; however, we can speculate that there may 
be a number of factors at play.  First, it is possible that tumors may have higher levels of α7 in 
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early stages of tumorigenesis (while the tumor has better prognosis and therefore correlates 
with increased survival) which would enhance the ability of the tumor to progress, but as the 
tumor advances to late stages α7 levels decrease and other factors are driving tumor 
progression.  Another possibility is that patients with higher levels of α7 may respond better to 
treatment modalities for undefined reasons, resulting in increased patient survival despite high 
levels of this receptor; while α3/β2 receptor subunits were involved in conferring resistance to 
chemotherapy drugs, α7 did not appear to have a role (184). It could also be that when there 
are higher levels of α7 present in a tumor, the receptors become desensitized to stimulation and 
are no longer able to be activated to exert their biological function; or alternatively they could 
become hyperactivated resulting in desensitization in a manner similar to the tumor inhibitory 
nAChR α4β2 which becomes desensitized in response to constant high affinity stimulation (79).    
Interestingly, we also found that high levels of α7 correlated with increased survival in men, but 
no difference was seen in women.  Why this is remains unclear at this time, but could be due to 
differences in the expression levels of the receptor in each gender or due to differences in other 
factors that might affect receptor function, such as nicotine uptake.  Studies have shown that 
men and women metabolize nicotine at different rates, and women have greater susceptibility to 
carcinogens than men (185).  Factors such as these may be involved in the differences 
observed.  The A549 and H460 cell lines used in the present study were both derived from male 
patients.  Further studies are warranted to answer these questions. 
The elucidation of regulation of nAChRs involved in nicotine-mediated cancer progression and 
the signaling mechanisms involved presents new opportunities to develop agents targeting 
these pathways, which could potentially improve therapeutic outcome for patients with smoking-
related cancers.  This study helps us to better understand the pathophysiology of such disease, 
specifically in the context of nicotine-mediated promotion of NSCLC. 
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CHAPTER FOUR: 
NICOTINE AND E-CIGARETTES REGULATED SOX2 AND STEMNESS IN NSCLC 
Note to Reader 
Portions of this chapter are included in a manuscript in preparation to be submitted to Molecular 
Cancer Research in August 2016. Author contributions: Schaal, C. (writing, concept, design, 
figures, experiments), Namrata Bora-Singhal (concept, experiments), Durairaj Mohan Kumar 
(experiments), Chellappan, S. (writing, concept, and design).  
Abstract 
 Lung cancer is the leading cause of cancer death and is highly correlated with cigarette 
smoking.  Nicotine, the addictive component of tobacco smoke, cannot initiate tumors, but can 
promote proliferation, migration, and invasion of cells in vitro and promote growth and 
metastasis of tumors in vivo.  This nicotine-mediated tumor progression is facilitated through 
activation of nicotinic acetylcholine receptors (nAChRs), specifically the α7 subunit. More 
recently, nicotine has been implicated in promoting self-renewal of stem-like side-population 
cells from lung cancers. This subpopulation of cancer stem-like cells has been implicated in 
tumor initiation, generation of entire heterogeneous tumor population, metastasis, dormancy, 
and drug resistance.   Here we demonstrate that nicotine can induce the expression of 
embryonic stem cell factor Sox2, which is indispensable for self-renewal and maintenance of 
stem cell properties in non-small cell lung adenocarcinoma (NSCLC) cells.  We further 
demonstrate that this occurs through a nAChR-Yap1-E2F1 signaling axis downstream of Src 
and Yes kinases. Data suggests Oct4 may also play a role in this process. Over the past few 
years, electronic cigarettes (e-cigarettes) have emerged as healthy alternatives to traditional 
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cigarette smoking as they do not contain tobacco; however, they do still contain nicotine.  To 
this extent we have investigated whether e-cigarettes can enhance tumor promoting properties 
similar to what we have reported with nicotine alone, and find that they can induce expression of 
Sox2 and mesenchymal markers as well as enhance migration and stemness of NSCLC cells. 
Introduction  
While our lab and others have demonstrated the ability of nicotine to enhance processes 
involved in the growth and metastasis of NSCLC, we have shown more recently that nicotine 
can enhance stemness in a subset of lung adenocarcinoma cells enriched in stem-like cell 
populations through the induction of c-Kit ligand/Stem Cell Factor (SCF).  SCF is known to 
promote self-renewal and differentiation of multiple stem cell types through the binding of its 
receptor, c-Kit (51, 186-188), and this finding reveals a novel mechanism by which nicotine can 
potentially regulate tumor progression. 
Tumors were traditionally thought to be a disease of clonal origin where a single transformed 
cell has the ability to give rise to heterogeneous tumor cell populations, with each daughter cell 
having the same capacity to give rise to more tumor cells. More recently, growing evidence 
supports the cancer stem cell model, which proposes that cancer stem-like cells (CSCs) arise 
through a reprogramming mechanism and these cells are responsible for tumor initiation, 
progression and maintenance (58-60). The model proposes that only CSCs are able to initiate 
tumors; these stem-like cells resemble traditional stem cells in that they are able to self-renew, 
divide asymmetrically, and are slow cycling (60), and have been implicated not only in tumor 
initiation, progression, and maintenance; but also in therapeutic resistance, dormancy, 
recurrence, and metastasis (60, 61).  Given these properties, understanding and targeting 
CSCs has become an important area of cancer research. 
Over the past decade or better, CSCs have been characterized and isolated using cell surface 
markers, which are differentially expressed in CSCs compared to non-stem-like, differentiated 
cancer cells. Various markers such as aldehyde dehydrogenase 1 (ALDH1) and CD133 
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positivity are effectively used for CSCs from cancers such as breast, colon, brain, pancreas, 
head and neck (62-65); however, there is no single marker ubiquitously expressed and used to 
identify lung cancer CSCs.  A subset of tumor cells enriched in CSCs can be isolated based on 
their ability to efflux Hoechst 33342 dye out of their nuclei through the ABCG2 drug transporter 
expressed on the cell membrane of the stem-like cells, and have been termed as side-
population cells, based on their distribution in flow cytometric sorting (59, 67, 68).  Our lab and 
others have shown that non-small cell lung cancer CSCs can be isolated using SP phenotype 
from cell lines as well as human tumor xenografts. Such cells were highly tumorigenic and 
produced highly invasive tumors in mice compared to the non-SP cells, and displayed stem-like 
properties such as the ability to self-renew, expressed epithelial-to-mesenchymal transition 
(EMT) markers as well as the classic embryonic stem cell (ESC) transcription factors Sox2, 
Oct4, and Nanog (59, 160).  We further demonstrated that EGFR-Src-AKT signaling axis acts 
upstream of Sox2 and inhibition of this pathway downregulates Sox2 and self-renewal ability of 
SP cells.  Sox2 itself was critical to maintain self-renewal of SP cells from NSCLC cell lines, 
compared to Oct4 and Nanog (59). Since we find that Sox2 ESC transcription factor is required 
to maintain NSCLC CSC stemness and that nicotine acts to enhance stemness, we sought to 
determine whether this nicotine-mediated induction of stemness acts through induction of Sox2.  
Here we report that nicotine can induce Sox2 through a Yap1/E2F1/Oct4 signaling axis.  We 
further report that e-cigarette extracts containing nicotine can induce self-renewal in a manner 
similar to nicotine, and e-cigarette extracts could induce Sox2 expression suggesting that 
exposure to nicotine, either through tobacco smoke or through the use of e-cigarettes, might 
have deleterious effects. 
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Results 
Nicotine and E-cigarettes Enhance Sox2 Expression and Self-Renewal of SP Cells 
Our lab had reported that the embryonic transcription factor Sox2 is indispensable for the 
maintenance of SP cell self-renewal and stemness (59), while Oct4 and Sox2 had a relatively 
lesser role. Further, stimulation with nicotine could enhance the self-renewal of SP cells in a 
receptor dependent manner (51).   We first sought to elucidate whether nicotine may enhance 
self-renewal through Sox2 using A549 and H1650 lung adenocarcinoma cell lines. Cells were 
serum starved for 24 hrs and stimulated with 2µM nicotine; induction of Sox2 was examined by 
immunofluorescence microscopy. Nicotine could induce Sox2 after 21 hours of stimulation in 
A549 cells (Figure 4.1A; similar induction was observed in human mesenchymal stem cells 
(Figure 4.1B), suggesting that the induction of Sox2 by nicotine is not restricted to cancer cells. 
 
Figure 4.1. Nicotine Enhances Sox2 Expression in NSCLC Cells and hMSCs.  (A and B) Immunofluorescent 
staining of A549 NSCLC cells and hMSCs shows increased levels of Sox2 after 21 hours of stimulation 
with 2µM nicotine compared to the control untreated cells. 
 
To determine the time course of the nicotine-mediation induction of Sox2, A549 cells were 
stimulated with nicotine for 18, 24, 48, 72, 96, and 120 hours and Sox2 expression was assessed 
by qRT-PCR and by western blotting. 2µM nicotine could induce Sox2 mRNA as well as protein 
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at 18 and 24 hours, an effect which was diminished by 48 hours and completely abolished by 72 
hours (Figure 4.2A and B).  To further confirm this induction, a Sox2 core promoter luciferase 
construct (Sox2-core-Luc) was tested in transient transfection experiments. This construct 
contains the region -530bp upstream through +238 of the transcription start site (TSS)(where 
TSS=0) on the Sox2 gene promoter driving the luciferase reporter. Nicotine induced Sox2-core-
luc activity by 2.7 and 2.2 fold after 21 hours in A549 and H1650 cells (Figure 4.2C).  Since we 
saw the peak induction of Sox2 occurring after 18-24 hours of nicotine stimulation, we used 21 
hours as the time point for the majority of experiments to follow.
 
Figure 4.2. Nicotine Enhances Sox2 Expression at the Promoter, Transcript, and Protein Levels.  (A) qRT-
PCR of A549 cells treated with 2µM nicotine for 18, 24, 48, 72, 96, or 120 hours show increased Sox2 
mRNA levels at 18 and 24 hours compared to untreated control cells; an effect diminished by 48 hours. (B) 
Western blot analysis showing similar results in A549 cells at the protein level. (C) Transient transfection 
of Sox2-core-luciferase promoter showing enhanced luciferase activity in response to 24 hours of 2µM 
nicotine stimulation in A549 and H460 cells. 
 
Similar experiments were conducted to assess whether e-cigarette extracts had similar ability to 
induce Sox2 levels comparable to nicotine. Immunofluorescence microscopy assays in A549 cells 
showed that extracts from all three brands of e-cigarettes, E-cig 1, E-cig2, and E-cig 3 could 
induce Sox2 after 21 hours of nicotine stimulation; similar induction was also observed in hMSCs, 
demonstrating that the induction is not specific to CSCs (Figure 4.3A and B). 
qRT-PCR and western blot experiments confirmed that E-cig1, E-cig2, and E-cig3 could induce 
Sox2 mRNA and protein expression in A549 cells,  after 21 hours of stimulation at levels 
comparable to nicotine (Figure 4.4A and B).  Transient transfection assays further demonstrated 
that extracts from each of the three brands of e-cigarettes could also induce Sox2-core-luc activity 
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after 21 hours of stimulation by 2.3, 2.2, and 2.3 folds in A549 cells, and by 2.2, 2.1, and 2.5 fold 
in H1650 cells (Figure 4.4C). 
 
Figure 4.3. E-cigarette Extracts Enhance Sox2 Expression in A549 Cells and hMSCs.  (A and B) 
Immunofluorescent staining showing that 2µM nicotine or 2µM of extracts from each of three brands of e-
cigarettes can enhance Sox2 expression levels after 24 hours, as compared to untreated control cells. 
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Figure 4.4. E-cigarette Extracts Enhance Sox2 Expression at the Promoter, Transcript, and Protein Levels.  
(A) qRT-PCR of A549 cells treated with 2µM nicotine or 2µM of each brand of e-cigarette for 24 hours 
shows increased Sox2 mRNA compared to untreated control cells. (B) Western blot analysis showing 
similar results in A549 cells at the protein level. (C) Transient transfection of Sox2-core-luciferase promoter 
showing enhanced luciferase activity in response to 24 hours of 2µM nicotine or 2µM e-cigarette extract 
stimulation in A549 and H460 cells. 
 
Since we had shown that nicotine could enhance the stemness and self-renewal ability of SP 
cells, we next determined whether this was observed with e-cigarette extracts. A549 and H1650 
cells were sorted as described in materials and methods, and SP and MP cells were plated 
separately. Cell sorting and self-renewal is depicted in Figure 4.5.   
At the time of plating, nicotine or extracts from each of the three brands of e-cigarettes was added 
to the cell media in the corresponding wells.  After 10 days cells were imaged to asses sphere 
formation as an indication of self-renewal using microscopy.  These experiments showed that e-
cigarette extracts could enhance sphere formation and self-renewal in a manner similar to nicotine 
in A549 and H1650 cells (Figure 4.6A and B). We further demonstrated that if similar experiments 
were conducted after Sox2 was depleted using siRNA, the ability of nicotine or e-cigarette extracts 
to enhance self-renewal was diminished in A549 or H1650 cells (Figure 4.7A and B). 
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Figure 4.5.  Depiction of SP Cell Sort and Self-Renewal Assay Parameters.  (A) Heterogenous cell 
populations are stained with Hoechst 33342 nuclear dye.  SP cells, enriched in cancer stem cell 
populations, have increased expression of the ABCG2 drug transporter, and are able to efflux the dye so 
the nucleus is not stained while the MP cells retain the dye.  Cells are then sorted by flow cytometry 
based on nuclear staining.  (B) To assess self-renewal capability, sphere formation assay are conducted 
by plating sorted cells at low density, onto ultra-low attachment surfaces, in stem cell selective media, and 
allowed to form spheres for 10 days. 
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Figure 4.6. E-cigarette Extracts Enhance Self-Renewal Ability of SP Cells.  (A and B) Self-renewal assays 
using A549 and H1650 NSCLC cells demonstrated that 2µM of nicotine or each of the three e-cigarette 
extracts could enhance sphere formation, indicative of self-renewal, compared to untreated controls. 
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Figure 4.7. Depletion of Sox2 Abrogates the Nicotine or E-cigarette Mediated Induction of Self-Renewal 
of SP cells.  (A and B) SP cells from A549 or H1650 cells treated with Sox2 siRNA show diminished 
ability to form spheres in the presence of 2µM nicotine or e-cigarette extracts in self-renewal assays. 
 
Nicotine-Mediated Induction of Sox2 Occurs Through a nAChR-Yap1-E2F1 Axis 
We next sought to elucidate the mechanism by which nicotine induces expression of Sox2.  
Previous studies have shown the nicotine exerts a number of tumor promoting properties such 
as proliferation, migration, and invasion through the binding to and activation of α7 nAChR, and 
that the nicotine-mediated activation of these receptors results in the transcriptional activity of 
E2F1 transcription factor (21, 22, 24, 159).  We have also previously reported that Yes 
Associated Protein 1 (Yap1), which is a transcriptional co-activator and the major effector of the 
Hippo signaling pathway, binds to Oct4 embryonic stem cell transcription factor on the Sox2 
promoter to regulate both Sox2 expression as well as the stem-like functions of cancer stem-like 
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cells.  Induction of Sox2 by Yap1 occurs independent of TEAD2 transcription factor, which is a 
well documented binding partner and mediator of Yap1 functions (160).  In this context, we 
depleted α7 nAChR, E2F1, Yap1, Oct4, or Tead2 using siRNA in A549 cells, stimulated with 
nicotine, and conducted western blot experiments; it was found that depletion of α7 nAChR, 
E2F1, or Yap1 could abrogate nicotine-mediated induction of Sox2 at the protein level (Figure 
4.8A).  To verify that the siRNAs used could reduce the expression of the indicated factors, 
transient transfection experiments were conducted in untreated A549s cells demonstrating that 
siRNAs targeting α7 nAChR, E2F1, Yap1, Oct4, Sox2, or Tead2 effectively reduced the  
corresponding protein level of each, as shown by western blot (Figure 4.8B-E). This led us to 
hypothesize that perhaps downstream of nicotine binding to the α7 nAChR, Yap1 is being 
activated to bind E2F1 on the Sox2 promoter to induce its expression.   
 
 
Figure 4.8. Depletion of α7 nAChR, E2F1, or Yap1 Could Abrogate Nicotine-Mediated Induction of Sox2.  
(A) Western blot analysis showing the protein levels of Sox2 to be reduced after transfection using siRNA 
targeting α7 nAChR, E2F1, or Yap1 followed by nicotine stimulation, compared to control scrambled 
siRNA transfected nicotine stimulated A549 cells. (B-E) Western blot analysis verifying the siRNA 
mediated depletion of E2F1, Sox2, Oct4, Yes1, TEAD2, and Yap1 in A549 cells.  Upon depletion of each 
factor, corresponding protein levels are seen to be reduced as compared to scrambled siRNA transfected 
control cells. 
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Sox2 Gene Expression is Regulated by E2F1, and Nicotine Enhances E2F1 Binding to Sox2 
To determine whether E2F transcription factors bind to the Sox2 gene promoter, Genomatix 
MatInspector Analysis Software was used to analyze a 1500bp region upstream of the Sox2 TSS 
for potential E2F binding sites; 19 predicted E2F binding sites were detected on this promoter 
region (Figure 4.9A).  Primers were designed spanning four different regions of the Sox2 promoter 
and chromatin immunoprecipitation assays were carried out to validate whether E2Fs bound to 
the predicted regions. E2F1  and to a lesser extent E2F2 and E2F3 could bind to a region –104 
through –259bp upstream of TSS (denoted as F1R1) in A549 cells; E2F1, E2F2, and E2F3 could 
also bind to a region could bind to a region –266 through –497bp upstream of TSS denoted as 
F2R2; E2F1 and to a lesser extent E2F2 and E2F3 could bind could to a region –1078 through –
1233bp upstream of TSS denoted as F3R3; and E2F1 and to some extent E2F2 could bind to a 
region –1414 through –1433bp upstream of TSS denoted as F4R4.  An irrelevant IgG antibody 
was used as a negative control for these experiments, and showed no amplification for any region 
(Figure 4.9B).   
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Figure 4.9. E2Fs have Multiple Predicted Binding Sites and can Associate with the Sox2 Promoter. (A) 
Schematic representation of  a 1500bp region of the Sox2 gene promoter showing potential E2F binding 
sites as green ovals.  Arrows represent the position of primers spanning E2F and STAT bindig sites used 
for ChIP assays. (B) ChIP-PCR assays in A549 cells showing binding of E2F1 and to a lesser extent 
E2F2 and E2F3 could bind to a region –104 through –259bp upstream of TSS (F1R1); E2F1, E2F2, and 
E2F3 could bind to a region–266 through –497bp upstream of TSS ( F2R2); E2F1 and to a lesser extent 
E2F2 and E2F3 could bind could to a region –1078 through –1233bp upstream of TSS (F3R3); and E2F1 
and to some extent E2F2 could bind to a region –1414 through –1433bp upstream of TSS 
(F4R4).Sonicated DNA was used as input control, and there was no detectable amplification from 
irrelevant IgG, used as negative control. 
 
Given that E2Fs could bind to the Sox2 promoter, transient transfection experiments were 
conducted to determine whether E2Fs could regulate Sox2 expression.  It was found that the 
transcriptionally active E2F family members (E2F1-3) could induce Sox2-core-luc activity by 2.3, 
1.8, and 1.8 fold respectively, while little or no effect was seen with the inactive E2F4 and E2F5 
(0.7 and 1.0 fold respectively) in A549 cells (Figure 4.10).   
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Figure 4.10.  E2F1-3 can Induce Sox2-luciferase Activity.  Transient transfection of A549 cells using 
0.5ug of Sox-core-luciferase showed that co-transfection using 1.0ug of E2F1, E2F2, or E2F3 could 
induce promoter activity, while little to no difference was seen with E2F4 or E2F5. 
 
To further assess whether the association of E2F1 with the Sox2 promoter was responsive to 
nicotine stimulation, A549 cells were serum starved and treated with nicotine, and ChIP assays 
were conducted.  It was found which that nicotine could enhance recruitment of E2F1 to the Sox2 
promoter after 18 hours of stimulation, and both the F1R1 region -104 through -259bp and the 
F2R2 region -266 through -497bp upstream of TSS (Figure 4.11A and B).   
 
Figure 4.11.  Nicotine Enhances the Recruitment of E2F1 Transcription Factor to the Sox2 Promoter.  (A 
and B) ChIP-PCR assays demonstrated that after 18 hours of stimulation with 2µM nicotine, there was 
increased association of E2F1 to the F1R1 and F2R2 regions on the Sox2 promoter in A549 cells 
compared to control serum starved cells. 
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Binding of Yap1 to E2F1 is Enhanced with Nicotine  
It has been suggested that Yap1 could regulate E2F1-mediated transcription.  Given that Yap1 
can regulate Sox2 expression, and since E2F1 was found to associate with the Sox2 promoter, 
we next examined whether Yap1, could co-localize or interact with E2F1 and if this was 
sensitive to nicotine or e-cigarette extract stimulation.  Double immunofluorescence experiments 
showed that Yap1 and E2F1 co-localized in A549 cells: treatment with nicotine or extracts from 
each of the three e-cigarette brands enhanced this interaction (Figure 4.12). 
 
Figure 4.12. Yap1 and E2F1 Colocalize in Cells, and this Interaction is Increased in the Presence of Nicotine 
or E-cigarette Extracts.  Double immunofluorescent staining of E2F1 (green) and Yap1 (red) showing 
colocalization of the two proteins in A549 cells.  Stimulation with 2µM nicotine or e-cigarette extracts 
enhanced colocalization after 24 hours. 
 
Similarly, proximity ligation assays (PLA) (161) were conducted to determine whether Yap1 and 
E2F1 proteins exist in close proximity within the cell, and at what point in time this occurs.  PLA 
is able to detect proteins within a 40nm range of one another, which generally indicates a direct 
physical interaction, and this can be visualized as individual foci by confocal microscopy.  These 
assays showed that Yap1 and E2F1 existed in close proximity of one another, and the 
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interaction was enhanced by nicotine as well as extracts from each of the three brands of e-
cigarettes.  We further find that this effect increased from 6 to 12 to 18 to 24 hours of nicotine or 
e-cigarette extract stimulation, coinciding with the time points at which Sox2 is induced (Figure 
4.13). 
 
 
 
Figure 4.13. Yap1 Associates with E2F1 Transcription Factor within Close Proximity and this is Enhanced 
by Nicotine or E-cigarette Extracts.  Proximity ligation assay (PLA) conducted on A549 cells demonstrated 
association of Yap1 and E2F1 proteins indicated as red foci; this association was enhanced in response 
to 2µM nicotine or e-cigarette stimulation and increased over time beginning at 6 hours through 18 and 24 
hours (the time points at which we find Sox2 to be induced by nicotine and e-cigarette extracts). 
 
To further confirm the physical interaction of Yap1 and E2F1 proteins, immunoprecipitation-
western blot experiments were conducted; these showed that Yap1 could physically interact 
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with E2F1 in untreated A549 and H1650 cell lines.  Yap1 could be detected in E2F1 
immunoprecipitates, by western blotting, and vice versa. An irrelevant IgG was used as a 
negative control in both cases to establish the specificity of the assay (Figure 4.14A and B). 
   
Figure 4.14.  Yap1 and E2F1 Proteins Physically Interact.  (A) Yap1-E2F1 binding is detected by 
immunoprecipitation with E2F1 antibody followed by western blot with Yap1 antibody in A549 and H1650 
cells. (B) Reciprocally, this is shown by immunoprecipitation with Yap1 antibody followed by western blot 
with E2F1 antibody.  Normal IgG was used as a negative control. 
 
Since we had previously reported that Yap1 could induce Sox2 expression and here we find that 
E2F1 not only induces Sox2 expression but can also interact with Yap1, we next sought to 
determine whether Yap1 and E2F1 cooperatively induce the Sox2 promoter.  Transient 
transfection experiments showed that Yap1 or E2F1 alone could induce Sox2-core-luc activity 
by 1.8 and 2.7 fold respectively; when both were transfected together, they showed an 6.2 fold 
induction of Sox2-core-luc activity, indicating a co-operative effect (Figure 4.15).  
 
 
Figure 4.15. Yap1 and E2F1 have an Additive Effect on Induction of Sox2-luciferase Activity.  A549 cells 
transfected with 0.5ug Sox2-core-luciferase showed increased activity when co-transfected with 1.0ug 
E2F1 or Yap1 separately, and this effect was further enhanced when E2F1 and Yap1 were co-transfected 
together. 
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Yap1 and E2F1 Association with the Sox2 Promoter is Enhanced with Nicotine 
To further interrogate whether Yap1 and E2F1 mediate Sox2 expression in response to nicotine 
stimulation, we conducted ChIP experiments on A549 cells stimulated with nicotine for 21 hours. 
It was found that association of both E2F1 and Yap1 proteins to the Sox2 promoter was 
enhanced in response to nicotine, compared to unstimulated, serum-starved cells.  Interestingly, 
we also found that the presence of known chromatin modifiers on the promoter was altered with 
nicotine.  Histone 3 tri-methylation of lysine 27 (H3K27me3) is known to contribute to gene 
repression and is present on silent chromatin, while histone 3 mono-methylation of lysine 27 
(H3K27me1) is conversely known to be associated with gene activation (189, 190).  Here we 
report that after 21 hours of nicotine stimulation in A549 cells the repressive marker H3K27me3 
has diminished association with Sox2 promoter while the activation marker H3K27me1 has 
enhanced association indicating that this promoter becomes activated in response to nicotine 
(Figure 4.16).  Further, previous literature has postulated that H3K27me3 repression is 
associated with maintenance of ESC pluripotency.  Studies mapping polycomb repressive 
complex 2 (PRC2) (which catalyzes H3K27me3 modifications) across the entire human ESC 
genome found that PRC2 is distributed across large portions of genes occupied by Sox2, Oct4, 
and Nanog transcription factors and these gene are heavily occupied by trimethylated H3K27 
nucleosomes acting to repress their expression until activated for differentiation (189, 191, 192).  
The key finding here is that the presence of K3K27me3 is not indicative of maintaining 
pluripotency through the Sox2 gene itself, but rather by co-occupying genes which Sox2 
transcription factor (as well as Oct4 and Nanog) turns on during differentiation; thus, the 
reduced association of H3K27me3 seen in response to nicotine is likely involved in the nicotine-
mediated activation of Sox2 expression, and Sox2 expression is known to be critical for 
maintaining stem-cell phenotypes in both NSCLC and ESC cells (59, 193). 
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Figure 4.16. Nicotine Enhances Recruitment of E2F1, Yap1, and H3K27me1 while Reducing H3K27me3 
Recruitment to the Sox2 Promoter at Region -266 Through -497bp Upstream TSS. ChIP-PCR assays 
showed that 21 hours of stimulation with 2µM nicotine could enhance association of E2F1, Yap1, and 
H3K27me1 (chromatin activation marker) to the Sox2 promoter, with a concomitant reduction in 
association of H3K27me3 (chromatin repressive marker) in A549 cells. 
 
Nicotine and E-cigarette Extracts Enhance Yap1 Expression 
During our experiments to determine the role of Yap1 and E2F1 in regulating Sox2 expression 
in the context of nicotine, we observed that the expression of Yap1 itself was enhanced upon 
nicotine stimulation.  Indeed, it has been reported that nicotine could induce Yap1 in certain cell 
types (194). Additional immunofluorescence microcopy experiments in A549 cells showed that 
nicotine and all three brands of e-cigarette extracts induced Yap1 levels after 21 hours.  
Nicotine could induce Yap1 expression in hMSCs as well, demonstrating that the induction is 
not specific to NSCLC cells (Figure 4.17A and B). 
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Figure 4.17. Nicotine and E-cigarette Extracts Enhance Yap1 Expression in A549 and hMSCs.  (A and B) 
Immunofluorescent staining showing that 2µM nicotine or 2µM of each of three brands of e-cigarette 
extracts can enhance Sox2 expression levels after 24 hours, as compared to untreated control cells. 
 
These results were confirmed at the mRNA level by qRT-PCR, which showed that nicotine and 
each brand of e-cigarette extracts induced Yap1 transcripts compared to serum starved control 
cells (Figure 4.18). 
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Figure 4.18.  Nicotine and E-cigarette Extract Enhance Yap1 mRNA Levels.  A549 cells treated with 2µM 
nicotine or e-cigarette extracts for 21 hours showed increased Yap1 mRNA expression compared to the 
untreated control cells as seen by qRT-PCR. 
 
Nicotine-Mediated Induction of Sox2 Occurs Through Src Kinases 
The Yap1 protein is known to be oncogenic as it promotes growth while inhibiting apoptosis, 
and is amplified or overexpressed in a number of cancer types (195-197).  It is named Yes-
associated-Protein 1 due to its ability to associate with SH3 domains of Src family tyrosine 
kinases which include Src, Yes, and Fyn (195).  Typically in quiescent cells, Yap1 is 
phosphorylated downstream of the tumor suppressive Hippo pathway, and when 
phosphorylated it is sequestered in the cytoplasm by 14-3-3 proteins resulting in degradation, 
thereby preventing its nuclear import (198).  Conversely, Yap1 is phosphorylated by Yes1 in 
embryonic stem cells, leading to its activation (2011).  Multiple studies have now reported that 
Yap1 has functions independent of the Hippo pathway, and it has further been shown that Yap1 
is a direct phosphorylation target of Src in a number of cancer cell lines, independent of the 
canonical Hippo pathway (199-201).  Our lab has previously reported that when nicotine binds 
to α7 nAChR, the β-arrestin-1 (β-arr-1) scaffolding protein is recruited and required to then 
activate phospho-Src kinase (p-Src), which mediates a number of downstream pathway 
effectors, including E2F1 transcriptional activity (46, 103).  We have additionally reported that 
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inhibition of the EGFR pathway including Src and PI3K could strongly inhibit Sox2 expression, 
thereby suppressing the self-renewal of SP cells enriched in NSCLC stem-like cells; and this 
occurred in a β-arrestin-1 (but not β-arrestin-2) dependent manner (59, 202). In this context we 
next sought to determine whether nicotine-mediated regulation of Sox2 by Yap and E2F1 was a 
result of the upstream activation of Src or Yes kinases.  Initial studies in A549 cells using 
inhibitors to Src/Yes/Fyn (Saracatinib), PI3K (Buparsilib), MEK1/2 (Trametinib), CDK4/6 
(Ribociclib), Rb-Raf interaction (RRD251), α7 nAChR (α-bungarotoxin), and Yap1 (visudyne) 
were carried out to determine which molecules known to be activated downstream of nicotine of 
might be involved.  Cells were treated with inhibitors as described in materials and methods, 
stimulated with nicotine for 21 hours, and Sox2 protein expression was assessed by western 
blotting. It was found that treatment with inhibitors to Src/Yes/Fin, PI3K, CDK4/6, or Yap1 could 
significantly abrogate nicotine-mediated induction of Sox2 (Figure 4.19). 
 
Figure 4.19. Inhibition of Src Family Kinases, PI3K, MEK1/2, CDK4/6, α7 nACHR, or Yap1 Could 
Abrogate Nicotine-Mediated Induction of Sox2.  A549 cells were serum starved, pre-treated with indicated 
inhibitors (Saracatinib, Buparsilib, Trametinib, Ribociclib, RRD-251, α-bungarotoxin, or visudyne), 
followed by stimulation with 2µM nicotine.  Western blot analysis showed that inhibitors targeting Src, 
PI3K, MEK1/2, CDK4/6, α7 nACHR, or Yap1 resulted in reduced protein levels of Sox2 compared to 
untreated, nicotine stimulated control cells. 
 
To further confirm whether Src or Yes played a role, we conducted depletion experiments in 
A549 cells using siRNA targeting β-arr-1, Src, or Yes, following which cells were stimulated with 
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nicotine for 21 hours and protein levels of Sox2 were assessed by western blotting.  Depletion 
of β-arr-1, Src, or Yes could reduce the induction of Sox2 following nicotine treatment (Figure 
14.20A).  To verify siRNA targeting β-arrestin-1, c-Src, or c-Yes1 could  deplete the 
corresponding proteins, transient transfections of each factor in untreated A549 cells followed 
by western blot analysis was carried out demonstrating that the siRNA transfections resulted in 
reduced levels of protein expression (Figure 4.20 B-C). 
 
Figure 4.20.  Depletion of β-arrestin-1, c-Src, or c-Yes Abrogated Nicotine-Mediated Induction of Sox2.  
(A) A549 cells transfected using siRNA, serum starved, and treated with 2µM nicotine for 21 hours.  
Western blot anlysis showed depletion of -arrestin-1, c-Src, or c-Yes abrogated nicotine-mediated 
induction of Sox2. (B andC) siRNA transfection followed by western blotting showing that depletion of Src, 
Yes1, or TEAD2 using siRNA effectively resulted in reduced protein levels of each of these factors. 
 
Additionally, double immunofluorescence experiments showed that depletion of Src using 
siRNA or inhibition using Saracatinib could abrogate the co-localization of Yap1 and E2F1 in 
response to nicotine stimulation after 21 hours (Figure 4.21).   
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Figure 4.21. Depletion or Inhibition of Src Kinase Abrogates Nicotine-Mediated Yap1/E2F1 Colocalization.  
(A) Double immunofluorescent experiments showed that depletion of Src using siRNA could abrogate the 
enhanced Yap1/E2F1 colocalization seen in response to 2µM nicotine stimulation for 21 hours. (B) 
Similarly, if Src family kinases were inhibited using Saracatinib (targeting Src, Yes, and Fyn), the nicotine-
mediated induction of Yap1/E2F1 colocalization was diminished. 
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These results were recapitulated in PLA experiments conducted in the same manner (Figure 
4.22).  Together, this data suggests that Src family kinases act upstream of Yap1 and E2F1 to 
regulate induction of Sox2 expression in response to nicotine. 
 
 
Figure 4.22. Depletion or Inhibition of Src Kinase Disrupts Nicotine-Mediated Yap1/E2F1 Interaction by 
PLA.  (A) PLA experiments showed that siRNA targeting Src could diminish the interaction of Yap1 and 
E2F1 proteins which was enhanced by 2µM nicotine after 21 hours, as indicated by red foci.  (B) 
Similarly, if Src family kinases were inhibited using Saracatinib (targeting Src, Yes, and Fyn), the nicotine-
mediated induction of Yap1-E2F1 protein-protein interaction was diminished. 
 
Oct4 may also Contribute to Nicotine-Mediated Induction of Sox2 
We had previously shown that Yap1 was elevated in cancer stem-like cells from NSCLC and 
was necessary for their self-renewal and ability to form angiogenic tubules; and these effects of 
Yap1 were mediated through the induction of Sox2 (160).  This was shown to occur through the 
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physical interaction of Yap1 with the Oct4 transcription factor on the Sox2 promoter independent 
of TEAD2 transcription factor (typically the primary mediator of Yap1 transcriptional effects); and 
Yap1-Oct4 interactions were found to be elevated in patient tumor samples compared to normal 
(160).  Further, depletion of Yap1 resulted in the inability of NSCLC cell lines to form tumors and 
metastasize in murine orthotopic lung implantation models, and the overexpression of Sox2 
could rescue this effect (160).  While this supports the important role Yap1 plays in modulation 
of stem-like functions through the regulation of Sox2, it lead us to question whether Yap1 
interaction with Oct4 might also play a role in nicotine-mediated induction of Sox2, in addition to 
Yap1-E2F1.  PLA experiments were conducted to determine whether nicotine or e-cigarette 
extracts had an effect on the interaction of Yap1 with Oct4 in A549 cells (Figure 4.23).  These 
assays showed that Yap1 and Oct4 existed in close proximity of one another, and the 
interaction was enhanced by nicotine as well as extracts from each of the three brands of e-
cigarettes similar to what we found for Yap1-E2F1 interaction. 
  
 
 
Figure 4.23. Yap1-Oct4 Association is Enhanced by Nicotine or E-cigarette Extracts.  Proximity ligation 
assay conducted on A549 cells demonstrated association of Yap1 and Oct4 proteins indicated as red 
foci; this association was enhanced in response to 2µM nicotine or e-cigarette extract stimulation for 21 
hours. 
 
We next sought to determine whether Oct4 had a role in nicotine induction of Sox2 itself.  
Transient transfection experiments were conducted using A549 cells and either the Sox2-luc 
reporter or a Sox2-luc reporter with the Oct4 site deleted to prevent binding (mutSox2-luc), 
followed by 24 hours of serum starvation and subsequently stimulation with 2µM nicotine or E-
cig 1 for 21 hours.  The Oct4 binding site is located in a region -266 through -497bp upstream of 
92 
 
the TSS on the Sox2 promoter, a region which additionally contains two predicted E2F binding 
sites. These assays showed that while nicotine or E-cig 1 could enhance Sox2-luc expression, 
neither could enhance expression of the mutSox2-luc suggesting that the Oct4 binding site is 
important for nicotine-mediated induction of Sox2-luc activity (Figure 4.24A).  Similar 
experiments were carried out using A549 cell lines stably expressing either Sox2-luc, mutSox2-
luc, or mutSox2-luc plus Yap1 overexpression.  These results additionally showed that in cells 
lacking an Oct4 binding site, nicotine or E-cig 1 could not induce Sox2-luc expression (Figure 
4.24B). 
 
Figure 4.24. Deletion of an Oct4 Binding Site on the Sox2 Promoter Abolishes the Ability of Nicotine or E-
cig 1 to Induce Sox2-luc Expression.  (A) Transient transfections of A549 cells showing that 2µM nicotine 
or E-cig 1 can induce Sox2-luc activity after 21 hours, an effect diminished using the mutSox2-luc reporter 
which has the Oct4 site deleted. (B)  2µM nicotine or E-cig 1 can induce Sox2-luc activity in cells stably 
expressing the construct after 21 hours; an effect which no longer occurs in cells stably expression 
mutSox2-luc or mutSox2-luc plus Yap1 overexpression. 
 
Since these results demonstrated the inability of nicotine to induce Sox2 expression when the 
Oct4 binding site was absent on the promoter, we next sought to determine whether depletion of 
Oct4 protein in addition to depletion of E2F1 protein could abrogate nicotine-mediated induction 
of Sox2, further implicating their roles in this process downstream of Yap1.  Transient 
transfections were conducted in A549 cells where Yap1, E2F1, or Oct4 were each depleted 
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using siRNA, were then transiently transfected using the Sox2-luc reporter, serum starved for 24 
hours, and stimulated with 2µM nicotine for 21 hours.  These experiments demonstrated that 
depletion of each of the three proteins could abrogate nicotine-mediated induction of Sox2, 
further supporting their roles this signaling cascade (Figure 4.25).  Overall, Yap1 seems to have 
an integral role in the regulation of Sox2 and its induction by nicotine, an effect which is 
moderated through is transcriptional collaboration with E2F1 and likely Oct4 as binding partners. 
 
Figure 4.25. Depletion of Yap1, E2F1, or Oct4 Each could Abrogate Nicotine-Mediated Induction of Sox2-
luc.  A549 cells were transiently transfected using siRNA to deplete Yap1, E2F1, or Oct4 followed by 
subsequent transfection with Sox2-luc reporter.  After 24 hours of serum starvation followed by 21 hours 
of 2µM nicotine stimulation, results showed that depletion of each of the three proteins resulted in the 
inability of nicotine to induce Sox2-luc activity. 
 
E-cigarette Extracts Enhance an Epithelial-Mesenchymal-Transition (EMT) Phenotype 
Epithelial-to-mesenchymal transition (EMT) is a normal process during development that is 
frequently activated during tumor progression allowing for a more migratory and invasive 
phenotype (203, 204).  Growing evidence suggests that activation of EMT induces the 
acquisition of stem cell properties in epithelial cells and that the induction of EMT and 
emergence of CSCs is strongly linked (203, 204).  We have previously reported that, in addition 
to nicotine enhancing CSC properties, it can induce a number of factors involved in EMT 
including the activation of mesenchymal markers such as vimentin, fibronectin, Zeb1, and Zeb2; 
suppression of epithelial markers such as e-cadherin; disruption of the tight junction protein ZO-
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1 thereby allowing for cell motility; and increased cell migration and invasion (21, 46).   Since we 
also find e-cigarette extracts are capable of enhancing CSC properties, we next interrogated 
whether e-cigarette extracts could further enhance EMT phenotypes, perhaps as a precursor to 
the acquisition of CSC phenotype.  At the mRNA level, we found that each of the three e-
cigarette brands could induce the mesenchymal markers vimentin, fibronectin, Zeb1, and Zeb2 
(Figure 4.26).  Immunofluorescent assays further demonstrated that e-cigarette extracts could 
disrupt ZO-1 tight junction protein with a concordant decrease in ZO-1 staining overall, and 
could additionally reduce levels of e-cadherin in A549 cells (Figure 4.27A and B).    
 
Figure 4.26. E-cigarette Extracts Induce mRNA Expression of Mesenchymal Markers Vimentin (VIM), 
Fibronectin (FN), ZEB1, and ZEB2.  qRT-PCR analysis of A549 cells serum starved followed by 
stimulation with 2µM nicotine show increased expression of VIM, FN, ZEB1, and ZEB2 mesenchymal 
markers which are upregulated during epithelial-to-mesenchymal transition. 
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Figure 4.27. E-cigarette Extracts Disrupt Tight Junction Protein ZO-1 and Epithelial E-cadherin (E-cad), 
with a concomitant decrease in expression of these two proteins. (A)  Treatment with 2µM of nicotine or 
each of the three e-cigarette extracts resulted in reduced expression of and translocation of ZO-1 from 
the cell membrane in A549 cells. (B)  Treatment with 2µM of nicotine or each of the three e-cigarette 
extracts resulted in reduced expression of and translocation of E-cadherin from the cell membrane in 
A549 cells.  
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Wound healing assays additionally demonstrated that e-cigarette extracts could enhance cell 
migration to a modest extent (Figure 4.28).  
 
Figure 4.28. E-cigarette Extracts Induce A549 Cell Migration in a Manner Similar to Nicotine.  Cells were 
plated at confluency, serum starved, and stimulated with 2µM nicotine or each of the three e-cigarette 
extracts.  Results demonstrate that e-cigarette extracts enhance migration to a modest extent. 
 
Overall, this data lays the ground work to suggest that e-cigarette extracts induce EMT 
phenotypes in a manner similar to what has previously been observed with nicotine. 
Discussion 
CSCs represent a subpopulation of tumor cells with increased tumor-initiating capability.  They 
can divide asymmetrically to replenish the heterogenous tumor bulk, and are highly efficient in 
initiating tumors upon implantation in animal models (61).  CSCs are resistant to various 
treatment modalities in part due to their enhanced ability to efflux drugs; additional reasons 
include  the fact that they are slower cycling, and they express higher levels of anti-apoptotic 
proteins. At the same time, complete mechanisms underlying the drug resistance of these cells 
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are not fully understood (61).  Additionally, these cells are thought to remain dormant and 
facilitate tumor recurrence and metastasis (61, 64).  Not surprisingly, based on these properties 
of CSCs, efforts are being made to elucidate mechanisms underlying the biology of CSCs in 
order to target this subpopulation. CSCs have different gene regulatory programs, including 
epigenetic changes, than the bulk tumor cells; understanding what these differences are, how 
the programs are regulated, will open up new opportunities for therapeutic targeting.   
We have previously reported that nicotine could enhance self-renewal of NSCLC SP cells.  Here 
we find a new mechanism through which this occurs, where nicotine induces Sox2 expression 
at 18 and 24 hour time points in NSCLC cells, through the Hippo pathway effector, Yap1. We 
also find that nicotine induces expression of Yap1 itself, and that the nicotine-mediated 
induction of Sox2 and Yap1 is not just specific to lung cancer cells but is also observed in 
human mesenchymal stem cells.  One previous report has demonstrated the ability of nicotine 
to induce Yap1 in esophageal squamous cell carcinoma (ESCC), and this occurred through 
nAChRs (194).  Interestingly, they find that Yap1 physically interacts with nAChRs and 
stimulation with nicotine could induce nuclear translocation and activation of Yap1 by disrupting 
its association with a negative regulatory complex in the cytoplasm composed of α-catenin, β-
catenin, and 14-3-3 proteins (194).  The molecular mechanisms regulating this process are not 
completely understood.   
Our prior studies have shown that Yap1 regulates Sox2 through the binding to Oct4 
transcription factor, facilitating self-renewal and vascular mimicry (160).  Here we report that 
E2F1 transcription factor can regulate the Sox2 promoter, and that Yap1 binds to E2F1 likely 
modulating this effect.  Further, we also find that nicotine or e-cigarette extracts can increase 
the binding of Yap1 to both E2F1 and Oct4.  Nicotine has been shown to induce E2F1 
transcriptional activity through a sequence of signaling events mediated downstream of nAChRs 
(103).  Upon nicotine binding, β-arrestin-1 scaffolding protein is recruited to the receptor and 
activates Src kinase which subsequently activates Raf-1.  Raf-1 then acts to phosphorylate the 
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Rb tumor suppressor protein which is typically bound to E2F1 during cellular quiescence, but 
once hypophosphorylated Rb dissociates from E2F1 allowing it to turn on a number of 
promoters involved in proliferation and survival (98).  We now find that this pathway might 
contribute to the induction of stemness, by facilitating the expression of Sox2.  
Our studies also suggest that Yap1 is induced by a non-canonical signaling mechanism in 
response to nicotine.  The Hippo signaling pathway has been demonstrated to have tumor 
suppressive roles, but is aberrantly altered in multiple cancers including those of the lung (205). 
Typically the activation of this pathway by upstream mediators Mst1/2 and Lats1/2 results in the 
inactivation of Yap1 through its phosphorylation, leading to cytoplasmic sequestration and 
degradation by 14-3-3 protein (205). Our results in NSCLC cells suggest that Yap1 is activated 
through Src and Yes kinases in response to nicotine; the role of the canonical Hippo signaling 
pathway in the induction remains unclear.   
Overall these studies suggest that upon nicotine binding to α7 nAChR, Src is activated and 
subsequently leads to Yap1 binding to E2F1 and/or Oct4, upregulating Sox2 expression, 
thereby enhancing self-renewal of CSCs. However, the role of Oct4 in this process is not fully 
clear.  When endogenous expression of Oct4 is knocked down, nicotine could still induce Sox2; 
in contrast, in transient transfection experiments using Sox-luciferase reporters showed that 
Oct4 binding sites on the Sox2 promoter were critical for nicotine to induce its expression. This 
was also found in cell lines stably transfected with a Sox2-Luciferase promoter, where mutation 
of the Oct4 site prevented nicotine-mediated induction of Sox2-luciferase. The molecular basis 
for the difference in the induction of endogenous Sox2 versus induction of a transfected Sox2-
luciferase reporter remains elusive at this time. It could be that other proteins are forming 
complexes with Oct4 or E2F1 to regulate Sox2, and these is somehow disrupted by mutation of 
the Oct4 binding site. It is also possible that post-translational modifications of the proteins 
involved or histone modifications on Sox2 promoter around the Oct4 binding site play a role. 
99 
 
Our lab had shown that nicotine induces the translocation of β-arrestin-1 scaffolding protein to 
the nucleus where it binds to E2F1 transcription factors to enhance transcription of E2F target 
genes (103).  This was found to occur through the formation of an oligomeric complex 
consisting of β-arrestin-1, E2F1, and p300 histone acetyltransferase proteins which facilitated 
the acetylation of histones and E2F1, acting to induce transcription of genes involved in 
proliferation and survival (103).  Our initial experiments show that depletion of β-arrestin-1 
reduced endogenous levels of Sox2; this raises the possibility that Yap1 is recruited to a 
complex with β-arrestin-1 and E2F1 on the Sox2 promoter. Alternately, β-arrestin-1 might be 
recruiting p300 to E2F1 independent of Yap1. It is additionally worth noting that other E2F family 
transcription factors may be involved, and their role is worth investigating.  These are novel 
findings that might have a significant impact on our understanding of how nicotine promotes 
self-renewal of stem-like cells from non-small cell lung cancer. Full elucidation of these 
mechanisms will shed light on the pathophysiology of smoking-related cancers, and reveal new 
pathways involved in promotion of CSC populations that can potentially be therapeutically 
exploited. 
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CHAPTER FIVE: 
SUMMARY AND CONCLUSIONS 
Summary of Novel Findings 
• Nicotine induces α7 nAChR promoter as well as mRNA and protein expression. 
• E2F1 and STAT transcription factors, which are activated downstream of nicotine, act to 
differentially regulate α7 nAChR through an overlapping binding site on the promoter. 
Nicotine induces Sox2 expression in NSCLC and hMSCs, through a Src-Yap1-E2F1 
axis; β-arr-1 and Oct4 may also be involved. 
• E2Fs bind to and induce Sox2 promoter, and nicotine enhances recruitment of E2F1 and 
Yap1 to the Sox2 promoter. 
• Depletion of Sox2 results in decreased self-renewal of SP cells. 
• E-cigarette extracts can enhance expression of α7 nAChR, Sox2, Yap1, and 
mesenchymal markers FN, VIM, ZEB, and ZEB2; while disrupting ZO-1 and E-cadherin. 
• E-cigarette extracts also enhance self-renewal ability of SP cells. 
Future Directions 
• Determine whether the differential regulation of α7 nAChR by E2F1 and STAT1 is time 
dependent and signal dependent. Do agents that induce STAT1 suppress α7 nAChR 
expression? 
• Analyze patient samples for E2F1, STAT1, and α7 nAChR interactions and levels in 
smokers compared to non-smokers. 
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• Conduct orthotopic mouse experiments using wild type cells compared to α7 nAChR null 
cells with two treatment groups: nicotine vs. control; to demonstrate whether α7 nAChR 
is required for nicotine-mediated induction of tumor growth and metastasis. 
• Elucidate the involvement of other E2F family members in nicotine-mediated induction of 
Sox2 as well as α7 nAChR. 
• Determine whether other proteins may interact with Yap1, E2F1, and Oct4 to regulate 
Sox2 expression in response to nicotine (ie: p300, β-arr-1). 
• Determine whether histone modifications or post-translation modifications play a role in 
nicotine-mediated induction of Sox2.  
• Analyze patient samples for E2F1, Yap1, and Sox2 interactions and levels in smokers 
compared to non-smokers. 
Conclusions 
Tobacco smoke is the single greatest preventable risk factor for cancer (206), yet is still 
responsible for an estimated 160,848 cancer related deaths each year in the United States, let 
alone globally. The current literature has shed light upon the multiple molecular mechanisms by 
which components of tobacco smoke can initiate tumor formation, impact cell cycle progression 
and proliferation, and promote tumor progression in multiple cancer types.  In a review of 10 
studies, it was found that people who continue to smoke after diagnosis of early stage lung cancer 
nearly double their risk of dying (207), and cessation of smoking after diagnosis improves multiple 
aspects of lung cancer including decreased risk of second tumors, increased overall well-being, 
improved immune response, and increased response to chemotherapeutic agents (125). There 
are a number of smoking cessation aids available, including varenicline, bupropion as well as 
various nicotine replacement therapy (NRT) agents such as transdermal patches, chewing gums, 
and now e-cigarettes.  
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Given that nicotine has tumor promoting properties, concerns have been raised regarding the 
deleterious effects of NRT on cancer therapy and survival. There have been limited efforts made 
to examine how exposure to nicotine through NRT products affects tumor growth or normal 
physiology including immune function in human subjects.  The advantage of NRT is that while 
tobacco smoke contains thousands of carcinogens, these are absent in NRT products, and hence 
NRT products are unable to initiate tumors. Supporting this contention, a model was developed 
to estimate mortality patterns associated with NRT use and success in smoking cessation; this 
compared the risks and benefits of NRT population-wide taking into account cancer-related safety 
of these products (208).  This study found that the benefits from successful cessation through the 
use of NRT outweighed the risks in terms of mortality and survival (208). Further, although a 
significant amount of additional studies need to be conducted to assess whether NRT affects the 
response to cancer therapy in general, it is reasonable to conclude that nicotine replacement 
therapy is significantly less harmful than smoking; nevertheless, it might be prudent to reduce the 
exposure to nicotine in any form for prolonged periods of time. 
While smoking cessation is the most effective method to reduce the risk of lung cancer, the 
elucidation of the signaling mechanisms as well as genetic alterations that facilitate smoking-
induced lung cancers has opened up new opportunities to develop novel therapeutic agents that 
target these pathways. While this process could be increasingly complex and painstakingly long, 
such efforts could hold promise for the treatment of tobacco-related cancers in the future.     
Given the multifaceted roles of nAChRs in initiation of tumors, promotion of cell proliferation, tumor 
growth and metastasis, and the additional association of the gene cluster encoding for the α3, α5, 
and β4 subunits of nAChRs with lung cancer and nicotine addiction, attempts have been made to 
target nAChRs to combat smoking induced lung cancers (157, 209).  Small molecule inhibitors 
and other agents have been under interrogation for use in the context of nAChRs in smoking 
related cancers, and the number of patented compounds selectively targeting nAChR subtypes 
are becoming increasing available; however, complete functional studies of these agents are still 
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limited; whether they work as agonists, antagonists, or partial agonists still needs to be elucidated; 
and which receptor subunits they target still needs to be determined (210).  Antagonists to the 
receptors facilitating oncogenic drivers as well as agonists to these receptors could both be viable 
therapeutic modalities, as antagonists block the receptor mediating pro-tumorigenic signaling 
events while agonists can lead to the release of factors such as GABA which can inhibit nicotine-
mediated tumor promotion (85).  As can be imagined, one major concern regarding the use of 
nAChR antagonists is the potential deleterious effect on the brain, central nervous system, 
neuromuscular system, and other vital cell and organ functions where these receptors are highly 
expressed and act to initiate signaling events (211). Further, many nAChR antagonists are known 
toxins such α-cobratoxin and α-bungarotoxin present in snake venom; although these have been 
found to abrogate nicotine-mediated tumor promotion in multiple contexts.     Since the main 
physiological roles of nAChRs are in the brain, long term treatment targeting these receptors may 
lead to things such as cognitive impairment, alterations in memory, alterations in sleep, and 
alterations in personality (210). Improved specificity of nAChR targeting agents in both the context 
of organ site as well as receptor subunit type could prove valuable for intervention of smoking-
related cancers.   
These results raise the intriguing possibility that targeting nAChRs, specifically α7 nAChR, might 
be a viable strategy to combat NSCLC, but a significant amount of additional studies would be 
needed to pursue this further. Given the potential toxicity of α7 antagonists and given the neuronal 
function of these receptors, targeting the downstream effectors of nAChRs might be an alternate 
approach that is worth considering; and therefore understanding detailed molecular pathways 
involved is of importance.  There is substantial literature detailing key oncogenic pathways such 
as the MAPK, JAK/STAT, PI3K, and other pathways which are activated downstream of the 
receptor; however, how expression of the receptor itself is regulated is not well understood.  Here 
we sought to elucidate the mechanism by which α7 nAChR is regulated.  We report that E2F1 
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and STAT1 transcription factors act to differentially regulate α7 nAChR expression through an 
overlapping binding site, perhaps by competitive interplay.  Nicotine itself has been shown to 
enhance expression of α7 nAChR, and we found that this additionally occurs through E2F1 and 
depletion of this transcription factor could abrogate nicotine-mediated induction of the receptor. 
We also discuss a subset of cells, cancer stem-like cells, which are a rare subpopulation within a 
tumor capable of giving rise to the entire heterogenous tumor.  These cells have gained attention 
as they are thought to be the cells which persist after therapeutic treatment, remain dormant, are 
responsible for recurrence, and metastasize to distal organs leading to mortality.  New therapeutic 
strategies are being developed to target this subset of cells in addition to the tumor bulk, with the 
intention of completely eradicating the tumor.  Since CSCs exhibit distinct molecular profiles, 
elucidating these profiles and the molecular underpinnings of the function of these cells is critical.  
It has been shown that nicotine acts to enhance gene expression and phenotype of CSCs, which 
raises the possibility that targeting the mechanisms by which nicotine mediates these events in 
smoking-related lung cancer may be beneficial.  Here we find that in NSCLC cells, nicotine 
induces the expression of Sox2 embryonic transcription factor, and this occurs through a Src 
family kinase-Yap1-E2F1/Oct4 signaling axis.  Further studies are warranted to elucidate whether 
targeting this pathway might effectively disrupt cancer stem cells specifically in the context of 
smoking related cancers, and potentially hold clinical utility. 
Interestingly, while the use of e-cigarettes has been gaining popularity and continues to be 
evaluated as an efficacious smoking cessation agent, we find that the nicotine present within the 
e-cigarette extracts acts to enhance a number of tumor promoting functions.  We find that 
extracts from three different brands of e-cigarettes can induce expression of α7 nAChR, Sox2, 
and Yap1; and also can enhance mesenchymal markers while repressing tight junction protein 
ZO-1 and epithelial E-cadherin as well as leading to their translocation from the cell membrane; 
features associated with EMT and cancers acquiring more aggressive phenotypes.  We 
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additionally show that e-cigarette extracts can enhance self-renewal of CSCs as well as 
migration of NSCLC cells in vitro.  Thus, while e-cigarettes may prove viable cessation agents, 
the use of these devices may act to promote progression of disease in patients with pre-existing 
tumors.  While a vast amount of information is known and continues to be generated regarding 
the role of nicotine in cancer progression, we have not found methods to effectively disrupt its 
ability to exert these effects so far; such an advance would have great utility for cancer patients 
who have history of smoking or who continue to smoke. For the agents that have already been 
developed, further studies are needed to evaluate their efficacy, specificity, and toxicities in pre-
clinical models to progress them more rapidly towards use in the clinic, and ultimately benefit to 
patients with smoking-related cancer.  
In summary, nicotine promotes a wide variety of tumor-promoting properties, almost in a 
pleiotropic manner, in a number of cancer types.  It acts to enhance multiple stages of tumor 
progression from proliferation, angiogenesis, chemoresistance, and survival of primary tumors, 
to EMT, migration, and invasion leading to tumor metastasis.  More recently, it has been shown 
that nicotine enhances the self-renewal of cancer stem-like cells, which are implicated in every 
stage of tumor initiation and progression, and are thought to be resistant to therapies, can 
remain dormant, and result in recurrence and dissemination.  In the context of patients who 
smoke and whose cancers were initiated as a result of smoking, targeting pathways which 
nicotine utilizes to exert its tumor-promoting functions seems to hold promise for therapeutic 
efficacy.  These pathways are depicted in Figure 5.1. 
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Figure 5.1.  Nicotine-Mediated Signaling Pathways Involved in Multiple Aspects of Tumor Initiation, 
Maintenance, and Progression.  Nicotine has been found to promote a variety of tumor promoting 
properties in multiple cancer types.  This occurs through the activation of molecular signaling cascades 
known to promote key processes in cancer progression including cell cycle progression, proliferation, 
survival, hypoxia, angiogenesis, EMT, cancer stem cell populations, drug resistance, and cancer stem 
cell populations.  Nicotine-mediated activation of these signaling cascades results in altered gene 
expression and altered secretion of factors such as VEGF, FGF, and SCF which in turn enhance these 
tumor promoting properties.  
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